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Abstract 
The synthesis and cytotoxic activities determination of new steroidal mono- and bis(thiazolidin-
4-ones) 4a‒f and 5a‒f have been performed. Their anticancer action was also evaluated in 
comparison to previously synthesized and reported corresponding steroidal 
thiosemicarbazones. All compounds were obtained as stereoisomeric mixtures with different 
configuration (E or Z) in the hydrazone moiety at the C-3 position. After several consecutive 
crystallizations diastereomerically pure major (E)-isomers of mono-thiazolidin-4-ones were 
isolated. The structure and stereochemistry of 2,4-thiazolidinedione,2-[(17-oxoandrost-4-en-3-
ylidene)hydrazone] were confirmed by X-ray analysis. A pathway for the formation of 
thiazolidin-4-one ring was proposed. The steroid thiazolidinone derivatives examined in this 
study exerted selective concentration-dependent cytotoxic activities on six tested malignant cell 
lines. Ten out of twelve examined compounds exhibited strong cytotoxic effects on K562 cells 
(IC50 values from 8.5 µM to 14.9 µM), eight on HeLa cells (IC50 values ranging from 8.9 µM 
to 15.1 µM) while against MDA-MB-361 cells six compouds exerted similar or even higher 
cytotoxic action (IC50 values from 12.7 µM to 25.6 µM) than cisplatin (21.5 µM) which served 
as a positive control. Eight of these ten compounds showed high selectivity in the cytotoxic 
action against HeLa and K562 cancer cell lines when compared with normal human fibroblasts 
MRC-5 and normal human PBMC. The study of mechanisms of the anticancer activity of the 
two selected compounds, mono- and bis(thiazolidin-4-one) derivatives of 19-norandrost-4-ene-
3,17-dione 4a and 5a, revealed that both of these compounds induced apoptosis in HeLa cells 
through extrinsic and intrinsic signalling pathways. 
Treatment of EA.hy926 cells with sub-toxic concentrations of these compounds led to the 
inhibition of cell connecting and sprouting, and tube formation. The synthesized compounds 
exhibited poor antioxidant activity. 
Keywords: Steroidal thiosemicarbazones; 1,3-Thiazolidin-4-ones; Cytotoxic activity; 
Apoptosis; Anti-angiogenic effect. 
1. Introduction 
Steroids are an important group of natural compounds playing a crucial role in many 
physiological and reproductive functions in the human body. Also, different types of steroids 
have been developed as drugs and anticancer agents [1]. The ability of hydrophobic steroid core 
to interact with cell membrane can enable transport of various functional groups or heterocyclic 
structures through them. As concerns the steroidal ligand-receptor binding mechanism, not only 
hydrophobic interactions but also hydrogen-bonding in some regions of the binding pocket is 
involved. Therefore, semisynthetic modifications involving the apolar sterane skeleton or the 
polar functional groups at C-3 and C-17 in the natural hormones may exert a significant 
influence on the binding affinity of the molecule [2]. Accordingly, the modifications of steroid 
molecules, by the addition of new functional groups or heterocyclic rings, resulting in new 
biological activities of these molecules, have become one of the major goals of steroid 
chemistry today.  
Recently we reported synthesis of new steroidal mono- and bis(thiosemicarbazones) and 
mono- and bis(1,3,4-thiadiazolines) obtained from several androstene derivatives 1a‒f (Fig. 1) 
and their cytotoxic activity in vitro [3]. Mono- and bis(thiosemicarbazones) were found to be a 
mixtures of (E)- and (Z)-isomers differing in configuration on the C(3)=N1 double bond. In all 
cases the main isomer adopted E configuration. The corresponding mono- and bis(1,3,4-
thiadiazolines) were formed as single heterocyclic compounds. 3-Thiosemicarbazones and 
3,17-bis(thiadiazolines) exhibited the best activity against all cancer cell lines used in this work 
[3]. The study of the mechanisms of anticancer activity revealed that these compounds induced 
apoptosis in HeLa cells, through extrinsic and intrinsic signalling pathways [3]. Additionally, 
these compounds showed a strong anti-angiogenic acitivity. The results from our research also, 
suggest that α,β-unsaturated thiosemicarbazone moiety at C-3 as well as the spiro heterocyclic 
substituent at C-17 position enhanced the activity of investigated compounds [3].  
Motivated by the results mentioned above and as a continuation of our work on the new 
heterocyclic steroid derivatives as biologically active molecules [3-5], we decided to prepare 
new steroidal heterocyclic compounds derived from previously synthesized mono- and 
bis(thiosemicarbazones) 2a‒f and 3a‒f (Fig. 1) [3] and to investigate their biological activities. 
It is well known that thiosemicarbazones have been used as intermediates for a great variety of 
heterocyclic products, such as thiazolidinones, thiohydantoines, and thioxopyrimidinediones 
[6]. Among them 4-thiazolidinone derivatives have attracted continuing atention due to their 
diverse biological activities [7]. In recent years, the synthesis of 4-thiazolidinone derivatives 
with anticancer activity against leukemia, melanoma, lung, colon, CNS, ovarian, renal, prostate 
and breast cancers cell lines has become a promising area of research [8,9]. To the best of our 
knowledge, very few steroidal thiazolidinones have been prepared so far [10-14] and their 
biological evaluation has been reported only for antibacterial action [15,16]. 
Here we describe the synthesis and configurational study of novel steroidal mono- and 
bis(thiazolidin-4-ones), and their in vitro cytotoxic activity. Since one of the goals of this 
study was to compare the activity of new heterocyclic derivatives with those reported 
earlier [3], the new compounds were tested against the same human malignant cell lines as the 
previous ones: cervical adenocarcinoma (HeLa), chronic myelogenous leukemia (K562), breast 
carcinoma (MDA-MB-453), breast adenocarcinoma (MDA-MB-361) colon adenocarcinoma 
(LS174) and lung adenocarcinoma (A549) cells. Besides, cytotoxicity of these compounds was 
tested on normal, human lung fibroblasts (MRC-5). The selectivity in the cytotoxic action of 
the most active compounds was evaluated against human normal peripheral blood mononuclear 
cells (PBMC). 
The specific objective of this study was to clarify the mechanisms of the cytotoxic actions 
of the tested compounds. Therefore, the morphological analysis by fluorescence microscopy 
and cell cycle analyses by flow cytometry were performed, as well as the effects on caspase-3, 
caspase-8 and caspase-9 activities of two selected derivatives. The anti-angiogenic potential of 
these compounds was also explored. Finally, the effects of two selected steroid derivatives on 
the gene expression levels of matrix metalloproteinases 2 and 9 (MMP2 and MMP9), and 
vascular endothelial growth factor A (VEGFA) were examined. 
2. Materials and methods  
2.1. Chemistry  
2.1.1. General methods 
All chemicals and solvents were reagent grade and purchased from commercial sources. 
Solvents were prepared according to the standard procedures prior to use. Starting steroid 
derivatives were recrystallized from a suitable solvent. Melting points (uncorrected) were 
determined on Digital melting point WRS-1B apparatus. IR spectra were recorded on a Perkin-
Elmer spectrophotometer FT-IR 1725X: ν in cm-1. NMR spectra (1D and 2D, 1H and 13C, 
DEPT, COSY, NOESY, HSQC, HMBC) were recorded in DMSO (if not otherwise stated) with 
a Bruker Avance 500 spectrometer (500 MHz for 1H, 125 MHz for 13C) or Varian Gemini-200 
spectrometer (200 MHz for 1H, 50 MHz for 13C) using TMS as internal standard. The spin 
multiplicities are indicated by the symbols, s (singlet), d (doublet), t (triplet), q (quartet), m 
(multiplet) and br (broad). Chemical shifts are expressed in ppm (δ) values and coupling 
constants (J) in Hz. The high-resolution mass spectra (HRMS) were taken with Agilent 6210 
LC ESI-TOF-MS or Thermo Scientific HESI-LTQ Orbitrap XL spectrometers. Reactions were 
monitored by thin-layer chromatography (TLC) performed on precoated Merck silica gel 60 
F254 plates using double development in various solvent systems. The chromatograms were 
visualized first with ultraviolet light (254 nm) and then TLC spots were detected by spraying 
with 50% aq. H2SO4 followed by heating. Flash column chromatography (FCC) was performed 
on silica gel Merck 0.040-0.063 mm.  
2.1.2. Synthesis of thiosemicarbazones and bis(thiosemicarbazones) 
Thiosemicarbazones 2a‒f and bis(thiosemicarbazones) 3a‒f were prepared as described 
earlier [3]. 
2.1.3. Synthesis of thiazolidin-4-one derivatives  
The preparation procedure of new steroidal thiazolidin-4-one derivatives was analogous to 
that described previously [17] with minor modifications. Into a solution of steroidal 
thiosemicarbazones (2a‒f or 3a‒f, 1 mmol) and anhydrous sodium acetate (123 or 246 mg, 1.5 
or 3 mmol) in absolute ethanol (30 or 50 mL), ethyl chloroacetate (122 or 244 mg, 1 or 2 mmol) 
was slowly added. The mixture was heated under reflux until the reaction was completed (for 
24‒45h, monitored by TLC), allowed to attain room temperature and then poured into water. 
The precipitate was separated by filtration, washed with cold water and cold ethanol and dried. 
The collected solid was recrystallized from methanol and the filtrate was further 
chromatographed by FCC (yield, eluent and the ratio mentioned in each experiment). The 
chemical and physical spectral characteristics of these products (4a-f and 5a-f) are given below.  
2.1.3.1. 2,4-Thiazolidinedione,2-[(17-oxoestr-4-en-3-ylidene)hydrazone] (4a). After filtration 
the product was recrystallized from MeOH to give 86 mg (22.3%) of pure 4a-E. Rf = 0.58 
(PhMe/EtOAc 6:4). Purification of the residue by flash chromatography (8:2 PhMe/EtOAc) 
gave E/Z (2:1) mixture of 4a (129 mg, 33.5%), which could not be further separated. Mp > 215 
°C (decomp.); IR (ATR/cm-1): 3130 (NH) 3082, 2941, 2857 (CH), 1731 (C=O), 1717 (C=O), 
1616 (C=N), 1327, 1248, 886. ESI-TOF-MS (m/z): [M+H]+ for C21H27N3O2S: calcd 386.18967, 
found 386.18961.  
 (4a-E). 1H-NMR (500 MHz, DMSO-d6): 0.75 (m, 1H, H-9), 0.84 (s, 3H, H3C-18), 0.99 (qd, J 
= 12.5, 3 Hz, 1H, Hα-7), 1.13‒1.33 (m, 4H, Hα-1, Hα-11, Hα-12, H-14), 1.40‒1,56 (m, 2H, H-
8, Hβ-15), 1.64 (br.d., J = 10.5 Hz, 1H, Hβ-12), 1.78‒1.90 (m, 3H, Hβ-7, Hβ-11, Hα-15), 1.97-
2.11 (m, 4H, Hβ-1, Hβ-2, H-10, Hα-16), 2.22 (td, J = 13.5, 3.0 Hz, 1H, Hα-6), 2.40 (dd, J = 19, 
8.5 Hz, 1H, Hβ-16), 2.47 (dt, J = 14, 3.0 Hz, 1H, Hβ-6), 3.04 (dt, J = 16.5, 4 Hz, 1H, Hα-2), 
3.79 (s, 2H, H2-5′), 5.95 (s, 1H, H-4), 11.72 (s, 1H, NH). 13C NMR (125 MHz, DMSO-d6): 
219.6 (s, C-17), 173.8 (s, C-4′), 162.3 (s, C-3), 161.2 (s, C-2′), 153.6 (s, C-5), 121.9 (d, C-4), 
49.4 (d, C-14), 49.1 (d, C-9), 47.1 (s, C-13), 41.5 (d, C-10), 39.2 (d, C-8), 35.3 (t, C-16), 34.4 
(t, C-6), 32.7 (t, C-5′), (31.2 (t, C-12), 29.7 (t, C-7), 26.1 (t, C-1), 25.2 (t, C-11), 24.3 (t, C-2), 
21.4 (t, C-15), 13.4 (q, C-18). 
(4a-Z) from the mixture E/Z=2:1. 1H-NMR (500 MHz, DMSO-d6): 0.75 (m, 1H, H-9), 0.84 (s, 
3H, H3C-18), 0.99 (qd, J = 12.5, 3 Hz, 1H, Hα-7), 1.13‒1.33 (m, 4H, Hα-1, Hα-11, Hα-12, H-
14), 1.40‒1,56 (m, 2H, H-8, Hβ-15), 1.64 (br.d., 1H, J = 10.5 Hz, 1H, Hβ-12), 1.78‒1.90 (m, 
3H, Hβ-7, Hβ-11, Hα-15), 1.97-2.11 (m, 3H, Hβ-1, H-10, Hα-16), 2.17-2.27 (m, 2H, Hβ-2, Hα-
6), 2.33-2.43 (m, 2H, Hα-2, Hβ-16), 2.48 (m, 1H, Hβ-6), 3.78 (s, 2H, H2-5′), 6.60 (s, 1H, H-4), 
11.72 (s, 1H, NH). 13C NMR (125 MHz, DMSO-d6): 219.6 (s, C-17), 174.0 (s, C-4′), 161.3 (s, 
C-3), 159.5 (s, C-2′), 155.4 (s, C-5), 111.8 (d, C-4), 49.4 (d, C-14), 49.1 (d, C-9), 47.1 (s, C-
13), 42.2 (d, C-10), 39.2 (d, C-8), 35.3 (t, C-16), 35.1 (t, C-6), 32.6 (t, C-5′), (31.2 (t, C-12), 
30.0 (t, C-2), 29.8 (t, C-7), 26.9 (t, C-1), 25.1 (t, C-11), 21.4 (t, C-15), 13.4 (q, C-18). 
2.1.3.2. 2,4-Thiazolidinedione,2-[(17-oxoandrost-4-en-3-ylidene)hydrazone] (4b). After 
filtration and purification of the crude product by FCC (8:2 PhMe/EtOAc) the E/Z (2:1) 
diastereoisomeric mixture (267 mg, 67%) was obtained. Crystallization from MeOH gave pure 
(E)- isomer (107 mg, 27 %). Rf = 0.61 (PhMe/EtOAc 6:4). Mp. 230.0‒236.4 °C. The rest was 
inseparable E/Z (2:3) mixture. IR (ATR/cm-1): 3082 (NH), 2924 (CH), 1721 (C=O), 1612 
(C=N), 1332, 1245. ESI-TOF-MS: m/z for C22H29N3O2S [M+H]
+: calcd 400.20532, found 
400.20549. 
(4b-E). 1H-NMR (500 MHz, DMSO-d6): 0.83 (s, 3H, H3C-18), 0.86 (m, 1H, H-9), 0.97 (qd, J 
= 12.5, 4.5 Hz, 1H, Hα-7), 1.06 (s, 3H, H3C-19), 1.16 (td, J = 13, 4 Hz, 1H, Hα-12), 1.21‒1.40 
(m, 3H, Hα-1, Hα-11, H-14), 1.51 (dtd, J = 3, 3.5, 3 Hz, 1H, Hβ-15), 1.56 (m, 1H, Hβ-11), 
1.62‒1.70 (m, 2H, H-8, Hβ-12), 1.81‒1.92 (m, 3H, Hβ-1, Hβ-7, Hα-15), 1.99 (dd, J = 9.5, 18 
Hz, 1H, Hα-16), 2.11 (td, J = 16, 4.5 Hz, 1H, Hβ-2), 2.30 (dtd, J = 5.0 Hz, 1H, Hα-6), 2.35‒
2.45 (m, 2H, Hβ-6, Hβ-16), 3.03 (dt, J = 16.5, 3.5 Hz, 1H, Hα-2), 3.795 (s, 2H, H2-5′), 5.88 (s, 
1H, H-4), 11.75 (s, 1H, NH). 13C NMR (125 MHz, DMSO-d6): 219.6 (s, C-17), 173.8 (s, C-4′), 
161.8 (s, C-3), 161.3 (s, C-2′), 157.8 (s, C-5), 121.2 (d, C-4), 53.3 (d, C-9), 50.2 (d, C-14), 46.9 
(s, C-13), 37.9 (s, C-10), 35.3 (t, C-16), 34.8 (t, C-1), 34.6 (d, C-8), 32.7 (t, C-5′), 31.7 (t, C-6), 
31.1 (t, C-12), 30.7 (t, C-7), 22.0 (t, C-2), 21.4 (t, C-15), 20.2 (t, C-11), 17.4 (q, C-19), 13.4 (q, 
C-18). 
(4b-Z) from the mixture E/Z=2:3. 1H-NMR (200 MHz, DMSO-d6): 0.83 (s, 3H, H3C-18), 0.92 
(m, 1H, H-9), 1.00 (m, 1H, Hα-7), 1.11 (s, 3H, H3C-19), 3.788 (s, 2H, H2-5′), 6.52 (s, 1H, H-
4), 11.73 (s, 1H, NH). 13C NMR (125 MHz, DMSO): 219.5 (s, C-17), 173.8 (s, C-4′), 160.7 (s, 
C-2′), 159.7 (s, C-3), 159.5 (s, C-5), 113.8 (d, C-4), 53.3 (d, C-9), 50.1 (d, C-14), 46.9 (s, C-
13), 38.5 (s, C-10), 35.8 (t, C-1), 35.3 (t, C-16), 34.5 (d, C-8), 32.6 (t, C-5′), 32.3 (t, C-6), 31.0 
(t, C-12), 30.9 (t, C-7), 27.0 (t, C-2), 21.4 (t, C-15), 20.0 (t, C-11), 17.5 (q, C-19), 13.4 (q, C-
18). 
2.1.3.3. 2,4-Thiazolidinedione,2-[(17-oxoandrosta-4,9(11)-dien-3-ylidene)hydrazone] (4c). 
After filtration the crude product was purified by flash chromatography (75:25 PhMe/EtOAc) 
to give 226 mg (57%) of 4c. After crystallization from MeOH pure (E)-isomer was obtained 
(88 mg, 22%). Rf = 0.63 (PhMe/EtOAc 6:4). Mp > 200 °C (decomp.). The rest was E/Z (1:1) 
mixture which could not be separated. IR (ATR/cm-1): 2965 (NH), 2953 (CH), 1741 (C=O), 
1724 (C=O), 1625 (C=N), 1334, 1252. ESI-TOF-MS: m/z for C22H27N3O2S [M+H]
+: calcd 
398.18967, found 398.18997.  
(4c-E). 1H-NMR (500 MHz, DMSO-d6): 0.79 (s, 3H, H3C-18), 1.00 (qd, J = 13, 3.5 Hz, 1H, 
Hα-7), 1.23 (s, 3H, H3C-19), 1.46 (m, H-14), 1.58 (dtd, J = 3, 2.5, 3 Hz, 1H, Hβ-15), 1.71 (td, 
J = 13.5, 4 Hz, 1H, Hβ-1), 1.92‒2.14 (m, 6H, Hα-1, Hβ-7, Hα-12, Hβ-12, Hα-15, Hα-16 ), 2.26 
(dtd, J = 5, 4, 5 Hz, 1H, Hβ-2), 2.32‒2.47 (m, 3H, Hα-6, H-8, Hβ-16), 2.54 (m, 1H, Hβ-6), 3.08 
(dt, J = 17, 3.5 Hz, 1H, Hα-2), 3.80 (s, 2H, H2-5′), 5.48 (d, J = 5.5 Hz, 1H, Hβ-11),  5.91 (s, 1H, 
H-4), 11.78 (s, 1H, NH). 13C NMR (125 MHz, DMSO-d6): 220.3 (s, C-17), 173.8 (s, C-4′), 
161.8 (s, C-3), 161.6 (s, C-2′), 156.3 (s, C-5), 146.3 (s, C-9), 121.4 (d, C-4), 116.4 (d, C-11), 
47.5 (d, C-14), 45.2 (s, C-13), 40.5 (s, C-10), 36.4 (d, C-8), 35.8 (t, C-16), 33.1 (t, C-12), 33.0 
(t, C-1), 32.7 (t, C-5′), 31.6 (t, C-6), 31.2 (t, C-7), 26.2 (q, C-19), 22.3 (t, C-2), 21.2 (t, C-15), 
13.6 (q, C-18). 
(4c-Z) from the mixture E/Z=1:1. 1H-NMR (500 MHz, CDCl3): 0.87 (s, 3H, H3C-18), 1.11 (m, 
1H, Hα-7), 1.28 (s, 3H, H3C-19), 1.48 (m, H-14), 1.61 (dtd, J = 3, 2.5, 3 Hz, 1H, Hβ-15), 1.91‒
2.02 (m, 2H, Hα-1, Hβ-1), 2.03‒2.21 (m, 5H, , Hβ-7, Hα-12, Hβ-12, Hα-15, Hα-16), 2.29‒2.45 
(m, 2H, Hα-6, H-8), 2.46‒2.50 (m, Hβ-6, Hβ-16), 2.57‒2.63 (m, 2H, Hα-2, Hβ-2), 3.77 (s, 2H, 
H2-5′), 5.51 (d, J = 5.5 Hz, 1H, Hβ-11), 6.52 (s, 1H, H-4). 13C NMR (125 MHz, CDCl3): 221.5 
(s, C-17), 173.8 (s, C-4′), 161.7 (s, C-3), 159.8 (s, C-2′), 159.4 (s, C-5), 145.9 (s, C-9), 117.1 
(d, C-11), 111.4 (d, C-4), 48.1 (d, C-14), 45.9 (s, C-13), 41.6 (s, C-10), 36.9 (d, C-8), 36.2 (t, 
C-16), 34.2 (t, C-1), 33.4 (t, C-12), 33.2 (t, C-5′), 32.8 (t, C-6), 31.4 (t, C-7), 27.8 (t, C-2), 26.8 
(s, C-19), 22.7 (t, C-15), 13.9 (q, C-18). 13C NMR (125 MHz, DMSO-d6): 220.2 (s, C-17), 173.8 
(s, C-4′), 159.5 (s, C-3), 161.5 (s, C-2′), 158.0 (s, C-5), 146.1 (s, C-9), 116.6 (d, C-11), 114.1 
(d, C-4), 47.5 (d, C-14), 45.2 (s, C-13), 41.3 (s, C-10), 36.3 (d, C-8), 35.8 (t, C-16), 34.0 (t, C-
1), 33.1 (t, C-12), 33.3 (t, C-6), 32.7 (t, C-5′), 31.2 (t, C-7), 27.4 (t, C-2), 26.4 (q, C-19), 22.2 
(t, C-15), 13.6 (q, C-18). 
2.1.3.4. 2,4-Thiazolidinedione,2-[[(11α)-11-hydroxy-17-oxoandrost-4-en-3-ylidene]hydra-
zone] (4d). After filtration the crude product was purified by flash chromatography (100:3 
CH2Cl2/MeOH) to give E/Z (3:1) mixture of 4d (357 mg, 86%) which could not be further 
separated. Rf = 0.34 (CH2Cl2/MeOH 20:1). Mp > 200 °C (decomp.); IR (ATR/cm
-1): 3480, 2928 
(NH), 1725 (C=O), 1620, 1558 (C=N), 1330, 1242. HESI-Orbitrap MS: m/z for C22H29N3O3S 
[M+H]+: calcd 416.20079, found 416.19876. 
(4d-E) from the mixture E/Z=3:1. 1H-NMR (500 MHz, DMSO-d6): 0.83 (s, 3H, H3C-18), 0.94‒
1.01 (m, 2H, Hα-7, H-9), 1.16 (s, 3H, H3C-19), 1.18 (m, 1H, Hα-12), 1.31(m, 1H, H-14), 1.48 
(dtd, J = 3, 2.5, 3 Hz, 1H, Hβ-15), 1.56 (td, J = 14, 3.5 Hz, 1H, Hα-1), 1.63 (qd, J = 11.5, 2.5 
Hz, 1H, H-8), 1.79‒1.90 (m, 3H, Hβ-7, Hβ-12, Hα-15), 2.02 (dd, J = 19, 9.5 Hz, 1H, Hα-16), 
2.16 (m, 1H, Hβ-2), 2.27‒2.33 (m, 2H, Hα-6, Hβ-6), 2.40 (dd, J = 19, 10.5 Hz, 1H, Hβ-16), 
2.58 (dt, J = 14, 4 Hz, 1H, Hβ-1), 2.875 (dt, J = 17, 4 Hz, 1H, Hα-2), 3.787 (s, 2H, H2-5′), 3.81 
(m, 1H, Hβ-11), 4.36 (d, J = 6.6 Hz, 1H,OH-11), 5.87 (s, 1H, H-4), 11.73 (s, 1H, NH). 13C 
NMR (125 MHz, DMSO): 218.6 (s, C-17), 173.8 (s, C-4′), 162.3 (s, C-3), 161.7 (s, C-2′), 158.7 
(s, C-5), 121.7 (d, C-4), 67.3 (d, C-11), 58.7 (d, C-9), 49.6 (d, C-14), 47.4 (s, C-13), 42.4 (t, C-
12), 39.5 (s, C-10), 36.4 (t, C-1), 35.4 (t, C-16), 34.1 (d, C-8), 32.7 (t, C-6), 32.5 (t, C-5′),  30.3 
(t, C-7), 22.4 (t, C-2), 21.3 (t, C-15), 18.2 (q, C-19), 14.3 (q, C-18). 
(4d-Z) from the mixture E/Z=3:1. 1H-NMR (500 MHz, DMSO-d6): 0.83 (s, 3H, H3C-18), 0.94‒
1.01 (m, 2H, Hα-7, H-9), 1.20 (s, 3H, H3C-19), 1.18 (m, 1H, Hα-12),  1.31(m, 1H, H-8), 1.476 
(dtd, J = 3, 2.5, 3 Hz, 1H, Hβ-15), 1.482 (m, 1H, H-14), 1.72 (m, 1H, Hα-1), 1.79‒1.90 (m, 3H, 
Hβ-7, Hβ-12, Hα-15), 2.02 (dd, J = 19, 9.5 Hz, 1H, Hα-16), 2.16 (m, 1H, Hβ-6), 2.26 (m, 1H, 
Hβ-2), 2,37 (m, 1H, Hα-6), 2.39 (m, 1H, Hα-2, overlapped with Hβ-16), 2.40 (dd, J = 19, 10.5 
Hz, 1H, Hβ-16), 2.53 (t, J = 4.5 Hz, 1H, Hβ-1), 3.784 (s, 2H, H2-5′), 3.81 (m, 1H, Hβ-11), 4.36 
(d, J = 6.6 Hz, 1H, OH-11), 6.50 (s, 1H, H-4), 11.73 (s, 1H, NH). 13C NMR (125 MHz, DMSO-
d6): 218.6 (s, C-17), 173.8 (s, C-4′), 161.7 (s, C-2′), 160.3 (s, C-5), 160.1 (s, C-3), 114.5 (d, C-
4), 67.2 (d, C-11), 58.8 (d, C-9), 49.5 (d, C-14), 47.4 (s, C-13), 42.4 (t, C-12), 40.2 (s, C-10), 
37.5 (t, C-1), 35.4 (t, C-16), 33.9 (d, C-8), 33.3 (t, C-6), 32.5 (t, C-5′), 30.7 (t, C-7), 27.2 (t, C-
2), 21.3 (t, C-15), 18.4 (q, C-19), 14.3 (q, C-18). 
2.1.3.5. 2,4-Thiazolidinedione,2-[[(11α)-11-(acetyloxy)-17-oxoandrost-4-en-3-ylidene]hydra-
zone] (4e). After filtration the crude product was purified by flash chromatography (100:1.5 
CH2Cl2/MeOH) to afford E/Z (3:1) mixture of 4e (352 mg, 77%). Rf = 0.59 (CH2Cl2/MeOH 
20:1). Mp > 200 °C (decomp.); IR (ATR/cm-1): 2967, 2934 (NH), 1733 (C=O), 1628, 1576 
(C=N), 1330, 1248. HESI-Orbitrap MS: m/z for C24H31N3O4S [M+H]
+: calcd 458.21135, found 
458.20976. 
(4e-E) from the mixture E/Z=3:1. 1H-NMR (500 MHz, CDCl3): 0.97 (s, 3H, H3C-18), 1.14 (qd, 
J = 12.5, 5 Hz, 1H, Hα-7), 1.18 (s, 3H, H3C-19), 1.26 (m, 1H, Hα-12), 1.36‒ 1.45 (m, 2H, H-9, 
H-14), 1.57 (dtd, J = 3, 2.5, 3 Hz, 1H, Hβ-15), 1.69 (td, J = 13.5, 4.5 Hz, 1H, Hα-1), 1.73‒1.86 
(m, 2H, Hβ-1, H-8), 1.97 (m, 1H, Hβ-7), 2.01 (s, 3H, OCOCH3), 2.013 (m, 1H, Hα-15), 2.13 
(dd, J = 19, 9.5 Hz, 1H, Hα-16), 2.20 (m, 1H, Hβ-12), 2.30 (m, 1H, Hβ-2), 2.34‒2.40 (m, 2H, 
Hα-6, Hβ-6), 2.49 (dd, J = 19, 10.5 Hz, 1H, Hβ-16), 2.96 (dt, J = 17, 4 Hz, 1H, Hα-2), 3.767 
(s, 2H, H2-5′), 5.24 (m, 1H, Hβ-11), 6.05 (s, 1H, H-4). 13C NMR (125 MHz, CDCl3): 218.2 (s, 
C-17), 173.6 (s, C-4′), 169.9 (c, OCOCH3), 163.5 (s, C-3), 161.4 (s, C-2′), 157.3 (s, C-5), 122.6 
(d, C-4), 70.4 (d, C-11), 55.7 (d, C-9), 49.6 (d, C-14), 47.4 (s, C-13), 39.5 (s, C-10), 38.2 (t, C-
12), 35.9 (t, C-1), 35.6 (t, C-16), 34.7 (d, C-8), 33.2 (t, C-5′),  32.9 (t, C-6), 30.6 (t, C-7), 22.4 
(t, C-2), 21.7 (q, OCOCH3), 21.6 (t, C-15), 18.4 (q, C-19), 14.2 (q, C-18). 
(4e-Z) from the mixture E/Z=3:1. 1H-NMR (500 MHz, CDCl3): 0.97 (s, 3H, H3C-18), 1.14 (qd, 
J = 12.5, 5 Hz, 1H, Hα-7), 1.22 (s, 3H, H3C-19), 1.26 (m, 1H, Hα-12),  1.39 (m, 1H, H-8), 1.49 
(m, 1H, H-9) 1.52‒1.63 (m, 2H, H-14, Hβ-15), 1.73‒1.86 (m, 2H, Hα-1, Hβ-2), 2.01 (m, 1H, 
Hα-15), 2.02 (s, 3H, OCOCH3), 2.13 (dd, J = 19, 9.5 Hz, 1H, Hα-16), 2.18 (m, 1H, Hβ-7), 2.20 
(m, 1H, Hβ-12), 2.29‒2.32 (m, 2H, Hα-6, Hβ-6), 2.43‒2.47 (m, 2H, Hβ-1, Hα-2), 2.49 (dd, J = 
19, 10.5 Hz, 1H, Hβ-16), 3.774 (s, 2H, H2-5′), 5.24 (m, 1H, Hβ-11), 6.55 (s, 1H, H-4). 13C NMR 
(125 MHz, CDCl3): 218.2 (s, C-17), 173.6 (s, C-4′), 169.9 (c, OCOCH3), 161.5 (s, C-3), 161.4 
(s, C-2′), 159.2 (s, C-5), 115.2 (d, C-4), 70.2 (d, C-11), 55.8 (d, C-9), 49.5 (d, C-14), 47.4 (s, C-
13), 30.2 (s, C-10), 38.2 (t, C-12), 36.9 (t, C-1), 35.6 (t, C-16), 34.6 (d, C-8), 33.3 (t, C-6), 33.1 
(t, C-5′), 30.8 (t, C-7), 27.6 (t, C-2), 21.7 (q, OCOCH3), 21.6 (t, C-15), 18.6 (q, C-19), 14.2 (q, 
C-18). 
2.1.3.6 2,4-Thiazolidinedione,2-[(20-oxopregn-4-en-3-ylidene)hydrazone] (4f). After filtration 
and crystallization from MeOH the E/Z mixture (9:1) of 4f (264 mg, 62%) was obtained. Rf = 
0.65 (PhMe/EtOAc 6:4). Mp > 170 °C (decomp.); IR (ATR/cm-1): 2932 (NH), 2876 (CH), 
1718, 1700 (C=O), 1618, 1576 (C=N), 1330, 1242. ESI-TOF-MS: m/z for C24H33N3O2S 
[M+H]+: calcd 428.23662, found 428.23653.  
(4f-E). 1H-NMR (500 MHz, DMSO-d6): 0.56 (s, 3H, H3C-18), 0.85 (td, J = 12, 3 Hz,1H, H-9), 
0.93 (qd, J = 12, 3.5 Hz, 1H, Hα-7), 1.04 (s, 3H, H3C-19), 1.10‒1.21 (m, 2H, H-14, Hβ-15), 
1.28‒1.42 (m, 3H, Hα-1, Hα-11, Hα-12), 1.46 (qd, J = 11, 2.5 Hz, 1H, H-8), 1.51‒1.59 (m, 2H, 
Hβ-11, Hβ-16), 1.62 (m, 1H, Hα-15), 1.74 (d, J = 12.5 Hz, 1H, Hβ-7), 1.88 (m, 1H, Hβ-1), 
1.96‒2.04 (m, 2H, Hβ-12, Hα-16), 2.05 (s, 3H, H3C-21), 2.10 (dtd, J = 4.5, 5, 4.5 Hz, 1H, Hβ-
2), 2.21‒2.34 (m, 2H, Hα-6, Hβ-6), 2.56 (t, J = 9 Hz, 1H, H-17), 3.04 (dt, J = 17, 3.5 Hz, 1H, 
Hα-2), 3.795 (s, 2H, H2-5′), 5.86 (s, 1H, H-4), 11.75 (s, 1H, NH). 13C NMR (125 MHz, DMSO-
d6): 208.5 (s, C-20), 173.8 (s, C-4′), 161.9 (s, C-3), 161.4 (s, C-2′), 158.0 (s, C-5), 121.1 (d, C-
4), 62.5 (d, C-17), 55.4 (d, C-14), 53.1 (d, C-9), 43.3 (s, C-13), 37.9 (t, C-12), 37.8 (s, C-10), 
35.1 (d, C-8), 34.8 (t, C-1), 32.6 (t, C-5′), 31.9 (t, C-7), 31.8 (t, C-6), 31.1 (q, C-21), 23.9 (t, C-
15), 22.2 (t, C-16), 22.0 (t, C-2), 20.9 (t, C-11), 17.3 (q, C-19), 13.0 (q, C-18). 
(4f-Z). 1H-NMR (500 MHz, DMSO-d6): 0.56 (s, 3H, H3C-18), 0.85 (m, 1H, H-9), 0.91 (m, 1H, 
Hα-7), 1.07 (s, 3H, H3C-19), 1.10‒1.21 (m, 2H, H-14, Hβ-15), 1.28‒1.42 (m, 3H, Hα-1, Hα-
11, Hα-12), 1.51‒1.59 (m, 3H, H-8, Hβ-11, Hβ-16), 1.62 (m, 1H, Hα-15), 1.77 (m, 1H, Hβ-7), 
1.89 (m, 1H, Hβ-1), 1.96‒2.04 (m, 2H, Hβ-12, Hα-16), 2.07 (s, 3H, H3C-21), 2.12 (m, 1H, Hβ-
6), 2.30(m, 1H, Hβ-2), 2.36 (m, 1H, Hα-6), 2.43 (td, J = 14.4, 4 Hz, 1H, Hα-2), 2.56 (t, J = 9 
Hz, 1H, H-17), 3.789 (s, 2H, H2-5′), 6.50 (s, 1H, H-4), 11.75 (s, 1H, NH). 13C NMR (125 MHz, 
DMSO-d6): 208.5 (s, C-20), 173.8 (s, C-4′), 161.4 (s, C-2′), 159.7 (s, C-5), 159.5 (s, C-3), 113.8 
(d, C-4), 62.5 (d, C-17), 55.4 (d, C-14), 53.4 (d, C-9), 43.3 (s, C-13), 37.9 (t, C-12), 38.6 (s, C-
10), 35.9 (t, C-1), 35.0 (d, C-8), 32.5 (t, C-5′), 32.6 (t, C-6), 32.2 (t, C-7), 31.1 (q, C-21), 27.1 
(t, C-2), 23.9 (t, C-15), 22.2 (t, C-16), 20.8 (t, C-11), 17.5 (q, C-19), 13.0 (q, C-18). 
2.1.3.7. Estr-4-ene-3,17-dione,3,17-bis[2-(4,5-dihydro-4-oxo-2-thiazolyl)hydrazone] (5a). 
After filtration the crude product was purified by flash chromatography (1:1 PhMe/EtOAc) to 
give inseparable E/Z (2:1) mixture of 5a (264 mg, 53%).. Rf = 0.28 (PhMe/EtOAc, 6:4). Mp > 
245 °C (decomp.); IR (ATR/cm-1): 2921 (NH), 2859 (CH), 1716 (C=O), 1620 (C=N), 1325, 
1239. ESI-TOF-MS: m/z for C24H30N6O2S2 [M+2H]
2+: calcd 250.10086, found 250.10125; m/z 
for C24H30N6O2S2 [M+H]
+: calcd 499.19444, found 499.11940. 
(5a-E). 1H-NMR (500 MHz, DMSO-d6): 0.77 (m, 1H, H-9), 0.89 (s, 3H, H3C-18), 0.99 (qd, J 
= 12.5, 3.5 Hz, 1H, Hα-7), 1.12‒1.19 (m, 2H, Hα-1, H-14), 1.27‒1,43 (m, 4H, H-8, Hα-11, Hα-
12, Hβ-15), 1.72‒1.81 (m, 2H, Hβ-7, Hα-15), 1.82‒1.89 (m, 2H, Hβ-11, Hβ-12), 1.96‒2.13 (m, 
3H, Hβ-1, Hβ-2, H-10), 2.23 (m, 1H, Hα-6), 2.35 (m, 1H, Hα-16), 2.43 (m, 1H, Hβ-6), 2.47 (m, 
1H, Hβ-16), 3.04 (dt, J = 16.5, 3.5 Hz, 1H, Hα-2), 3.74 (s, 2H, H2-5″), 3.79 (s, 2H, H2-5′), 5.95 
(s, 1H, H-4), 11.72 (s, 2H, 2NH). 13C NMR (125 MHz, DMSO-d6): 178.6 (s, C-17), 174.0 (s, 
C-4″), 173.8 (s, C-4′), 162.4 (s, C-3), 161.8 (s, C-2″), 161.3 (s, C-2′), 153.6 (s, C-5), 121.9 (d, 
C-4), 51.7 (d, C-14), 49.3 (d, C-9), 44.2 (s, C-13), 41.6 (d, C-10), 39.28 (d, C-8), 34.5 (t, C-6), 
33.8 (t, C-12), 32.7 (t, C(5′), 32.6 (t, C-5″), 30.4 (t, C-7), 27.9 (t, C-16), 26.1 (t, C-1), 25.6 (t, 
C-11), 24.4 (t, C-2), 22.8 (t, C-15), 16.9 (q, C-18).  
(5a-Z). 1H-NMR (500 MHz, DMSO-d6): 0.77 (m, 1H, H-9), 0.89 (s, 3H, H3C-18), 0.99 (qd, J 
= 12.5, 3.5 Hz, 1H, Hα-7), 1.25 (m,1H, Hα-1), 1.27‒1.43 (m, 5H, H-8, Hα-11, Hα-12, H-14, 
Hβ-15), 1.72‒1.81 (m, 2H, Hβ-7, Hα-15), 1.82‒1.89 (m, 2H, Hβ-11, Hβ-12), 2.06‒2.13 (m, 2H, 
Hβ-1, H-10), 2.23 (m, 1H, Hα-6), 2.27 (m, 1H, Hβ-2), 2.30‒2.41 (m, 3H, Hα-2, Hβ-6, Hα-16), 
2.47 (m, 1H, Hβ-16), 3.74 (s, 2H, H2-5″), 3.78 (s, 2H, H2-5′), 6.57 (s, 1H, H-4), 11.75 (s, 2H, 
2NH). 13C NMR (125 MHz, DMSO-d6): 178.6 (s, C-17), 174.0 (s, C-4″), 173.9 (s, C-4′), 160.2 
(s, C-3), 161.8 (s, C-2″), 160.6 (s, C-2′), 155.5 (s, C-5), 121.7 (d, C-4), 51.6 (d, C-14), 49.5 (d, 
C-9), 44.2 (s, C-13), 42.4 (d, C-10), 39.33 (d, C-8), 35.2 (t, C-6), 33.8 (t, C-12), 32.7 (t, C(5′), 
32.6 (t, C-5″),  30.6 (t, C-7), 27.9 (t, C-16), 26.9 (t, C-1), 25.5 (t, C-11), 29.9 (t, C-2), 22.8 (t, 
C-15), 16.9 (q, C-18). 
2.1.3.8. Androst-4-ene-3,17-dione,3,17-bis[2-(4,5-dihydro-4-oxo-2-thiazolyl)hydrazone] (5b). 
After filtration and crystallization from CHCl3/MeOH a pure (E)- isomer of 5b was obtained 
(282 mg, 55%). The rest was complex mixture which could not be further separated. Rf = 0.25 
(PhMe/EtOAc, 6:4). Mp > 200 °C (decomp.); IR (ATR/cm-1): 3124, 2930 (NH), 2859 (CH), 
1715 (C=O), 1655, 1618 (C=N), 1338, 1243. ESI-TOF-MS: m/z for C25H32N6O2S2 [M+2H]
2+: 
calcd 257.10868, found 257.10937; m/z for C25H32N6O2S2 [M+H]
+: calcd 513.21009, found 
513.21057. 
(5b-E). 1H-NMR (500 MHz, DMSO-d6): 0.88 (s, 3H, H3C-18), 0.89 (m, 1H, H-9, overlapped 
with H3C-18), 0.97 (qd, J = 12.5, 3.5 Hz, 1H, Hα-7), 1.07 (s, 3H, H3C-19), 1.13 (m, 1H, H-14), 
1.26‒1.47 (m, 4H, Hα-1, Hα-11, Hα-12, Hβ-15), 1.55‒1.67 (m, 2H, H-8, Hβ-11), 1.72‒1.92 
(m, 4H, Hβ-1, Hβ-7, Hβ-12, Hα-15), 2.11 (dtd, J = 5, 2, 5 Hz, 1H, Hβ-2), 2.27 (m, 1H, Hα-6), 
2.35 (m, 2H, Hβ-6, Hβ-16), 2.47 (m, 1H, Hα-16), 3.04 (dt, J = 17, 3.5 Hz, 1H, Hα-2), 3.74 (s, 
2H, H2-5″), 3.79 (s, 2H, H2-5′), 5.87 (s, 1H, H-4), 11.72 (s, 2H, 2NH). 13C NMR (125 MHz, 
DMSO-d6): 178.5 (s, C-17), 173.8 (s, C-4′ and C-4″), 162.0 (s, C-3), 161.4 (s, C-2′ and C-2″), 
157.9 (s, C-5), 121.1 (d, C-4), 53.5 (d, C-9), 52.4 (d, C-14), 43.9 (s, C-13), 37.9 (d, C-10), 34.8 
(t, C-1), 34.7 (d, C-8), 33.8 (t, C-12), 32.6 (t, C-5′ and C-5″), 31.7 (t, C-6), 31.3 (t, C-7), 27.8 
(t, C-16), 22.9 (t, C-15), 22.0 (t, C-2), 20.4 (t, C-11), 17.4 (q, C-19), 16.8 (q, C-18). 
2.1.3.9. Androsta-4,9(11)-diene-3,17-dione,3,17-bis[2-(4,5-dihydro-4-oxo-2-thiazolyl)hydra-
zone] (5c). After filtration the crude product was purified by flash chromatography (6:4 
PhMe/EtOAc) to give E/Z (2:1) mixture of 5c (260 mg, 51%) which could not be further 
separated. Rf = 0.25 (PhMe/EtOAc, 6:4). Mp > 200 °C (decomp.); IR (ATR/cm
-1): 2959 (NH), 
2925 (CH), 1726 (C=O), 1660, 1626 (C=N), 1324, 1240. ESI-TOF-MS: m/z for C25H30N6O2S2 
[M+2H]2+: calcd 256.10086, found 256.10172; m/z for C25H30N6O2S2 [M+H]
+: calcd 
511.19444, found 511.19440. 
(5c-E). 1H-NMR (500 MHz, DMSO-d6): 0.85 (s, 3H, H3C-18), 1.00 (qd, J = 13, 3.5 Hz, 1H, 
Hα-7), 1.22 (s, 3H, H3C-19), 1.33 (m, 1H, H-14), 1.43 (dbr.sd, J = 3 Hz, 1H, Hβ-15), 1.72 (td, 
J = 14, 5 Hz, 1H, Hβ-1), 1.92 (m, 1H, Hα-15), 1.95‒2.05 (m, 2H, Hα-1, Hβ-7), 2.05‒2.18 (m, 
2H, Hα-12, Hβ-12), 2.26 (m, 1H, Hβ-2), 2.29 (m, 1H, H-8), 2.35 (m, 1H, Hα-6), 2.39 (m, 1H, 
Hα-16), 2.52‒2.60 (m, 2H, Hβ-6, Hβ-16), 3.08 (dt, J = 17, 3.5 Hz, 1H, Hα-2), 3.76 (s, 2H, H2-
5″), 3.80 (s, 2H, H2-5′), 5.52 (d, J = 4.5 Hz, 1H, Hβ-11), 5.90 (s, 1H, H-4), 11.73 (s, 2H, 2NH). 
13C NMR (125 MHz, DMSO-d6): 178.5 (s, C-17), 173.9 (s, C-4″), 173.8 (s, C-4′), 161.8 (s, C-
3), 161.6 (s, C-2′), 161.5 (C-2″), 156.4 (s, C-5), 146.1 (s, C-9), 121.3 (d, C-4), 117.1 (d, C-11), 
49.6 (d, C-14), 42.4 (s, C-13), 40.5 (d, C-10), 36.3 (d, C-8), 36.1 (t, C-12), 32.9 (t, C-1), 32.7 
(s, C-5′), 32.6 (t, C-5″), 31.7 (t, C-6), 31.7 (t, C-7), 28.4 (t, C-16), 26.2 (q, C-19), 23.8 (t, C-
15), 22.4 (t, C-2), 17.1 (q, C-18). 
(5c-Z). 1H-NMR (500 MHz, DMSO-d6): 0.85 (s, 3H, H3C-18), 1.00 (qd, J = 13, 3.5 Hz, 1H, 
Hα-7), 1.26 (s, 3H, H3C-19), 1.43 (m, 1H, H-14, overlapped with Hβ-15), 1.43 (dbr.sd, J = 3 
Hz, 1H, Hβ-15), 1.83 (td, J = 13.5, 4 Hz, 1H, Hβ-1), 1.92 (m, 1H, Hα-15), 1.95‒2.05 (m, 2H, 
Hα-1, Hβ-7), 2.05‒2.18 (m, 2H, Hα-12, Hβ-12), 2.23 (m, 1H, Hα-6), 2.29 (m, 1H, H-8), 2.39 
(m, 1H, Hα-16), 2.42 (m, 1H, Hβ-2), 2.52‒2.60 (m, 3H, Hα-2, Hβ-6, Hβ-16), 3.76 (s, 2H, H2-
5″), 3.79 (s, 2H, H2-5′), 5.52 (d, J = 4.5 Hz, 1H, Hβ-11), 6.52 (s, 1H, H-4), 11.73 (s, 2H, 2NH). 
13C NMR (125 MHz, DMSO-d6): 178.5 (s, C-17), 173.9 (2s, C-4′ and C-4″), 161.5 (2s, C-2′ 
and C-2″), 159.5 (s, C-3), 158.2 (s, C-5), 146.0 (s, C-9), 117.2 (d, C-11), 114.1 (d, C-4), 49.6 
(d, C-14), 42.4 (s, C-13), 41.2(d, C-10), 36.3 (d, C-8), 36.1 (t, C-12), 34.0 (t, C-1), 32.7 (s, C-
5′), 32.6 (t, C-5″), 32.4 (t, C-6), 31.7 (t, C-7), 28.4 (t, C-16), 27.4 (t, C-2), 26.4 (q, C-19), 23.8 
(t, C-15), 17.1 (q, C-18). 
2.1.3.10. (11α)-11-Hydroxyandrost-4-ene-3,17-dione,3,17-bis[2-(4,5-dihydro-4-oxo-2-
thiazolyl)hydrazone] (5d). After filtration the crude product was purified by flash 
chromatography (100:5 CH2Cl2/MeOH) to give E/Z (4:1) mixture of 5d (320 mg, 61%) which 
could not be further separated. Rf = 0.30 (CH2Cl2/MeOH 20:1). Mp > 200 °C (decomp.). IR 
(ATR/cm-1): 3480, 2927 (NH), 1711 (C=O), 1615 (C=O), 1560 (C=N), 1331, 1240. HESI-
Orbitrap MS: m/z for C25H32N6O3S2 [M+H]
+: calcd 529.20556, found 529.20381. 
(5d-E). 1H-NMR (500 MHz, DMSO-d6): 0.88 (s, 3H, H3C-18), 0.94‒1.04 (m, 2H, Hα-7, H-9), 
1.17 (s, 3H, H3C-19), 1.20 (m, 1H, H-14, overlapped with H3C-19), 1.27‒1.39 (m, 2H, Hα-12, 
Hβ-15), 1.52‒1.63 (m, 2H, Hα-1, H-8), 1.68‒1.85 (m, 2H, Hβ-7, Hα-15), 2.08 (dd, J = 5, 12 
Hz, 1H, Hβ-12), 2.16 (dtd, J = 4.5, 4, 4.5 Hz 1H, Hβ-2), 2.22‒2.30 (m, 2H, Hα-6, Hβ-6), 2.39 
(dd, J = 19, 9 Hz, 1H, Hα-16), 2.50 (dd, J = 18.5, 9 Hz, 1H, Hβ-16), 2.58 (dt, J = 14, 4 Hz, 1H, 
Hβ-1), 2.88 (dt, J = 17, 3.5 Hz, 1H, Hα-2), 3.76 (s, 2H, H2-5″), 3.79 (s, 2H, H2-5′), 3.85 (m, 1H, 
Hβ-11), 4.32 (d, J = 6.5 Hz, 1H, OH-11), 5.86 (s, 1H, H-4), 11.72 (s, 1H, NH). 13C NMR (125 
MHz, DMSO-d6): 177.9 (s, C-17), 173.9 (s, C-4′), 174.0 (s, C-4″), 162.4 (s, C-3), 161.8 (s, C-
2″), 161.4 (s, C-2′), 158.9 (s, C-5), 121.7 (d, C-4), 67.4 (d, C-11), 58.4 (d, C-9), 51.9 (d, C-14), 
45.1 (t, C-12), 44.4 (s, C-13), 39.5 (s, C-10), 36.4 (t, C-1), 34.2 (d, C-8), 32.8 (t, C-6), 32.7 (t, 
C-5″), 32.6 (t, C-5′), 31.0 (t, C-7), 28.0 (t, C-16), 22.9 (t, C-15), 22.4 (t, C-2), 18.3 (q, C-19), 
17.8 (q, C-18). 
(5d-Z). 1H-NMR (500 MHz, DMSO-d6): 0.88 (s, 3H, H3C-18), 0.94‒1.04 (m, 2H, Hα-7, H-9), 
1.21 (s, 3H, H3C-19), 1.27‒1.39 (m, 3H, Hα-12, H-14, Hβ-15), 1.55 (m, 1H, H-8), 1.68‒1.85 
(m, 3H, Hα-1, Hβ-7, Hα-15), 2.08 (dd, J = 5, 12 Hz, 1H, Hβ-12), 2.10 (m, Hβ-6), 2.21 (m, 1H, 
Hβ-2), 2.39 (dd, J = 19, 9 Hz, 1H, Hα-16), 2.50 (dd, J = 18.5, 9 Hz, 1H, Hβ-16), 2.49 (m, 1H, 
Hβ-1), 3.76 (s, 2H, H2-5″), 3.79 (s, 2H, H2-5′), 3.85 (m, 1H, Hβ-11), 4.32 (d, J = 6.5 Hz, 1H, 
OH-11), 6.49 (s, 1H, H-4), 11.72 (br.s, 2H, 2NH). 13C NMR (125 MHz, DMSO-d6): 177.9 (s, 
C-17), 173.9 (s, C-4′), 174.0 (s, C-4″), 161.8 (s, C-2″), 161.4 (s, C-2′), 160.4 (s, C-3), 160.2 (s, 
C-5), 114.4 (d, C-4), 67.4 (d, C-11), 59.0 (d, C-9), 51.9 (d, C-14), 45.1 (t, C-12), 44.4 (s, C-13), 
39.8 (s, C-10), 37.6 (t, C-1), 34.1 (d, C-8), 33.4 (t, C-6), 32.7 (t, C-5″), 32.6 (t, C-5′), 31.4 (t, 
C-7), 28.0 (t, C-16), 27.3 (t, C-2), 22.9 (t, C-15), 18.5 (q, C-19), 17.8 (q, C-18). 
2.1.3.11. (11α)-11-(Acetyloxy)-androst-4-ene-3,17dione,3,17-bis[2-(4,5-dihydro-4-oxo-2-
thiazolyl)hydrazone] (5e). After filtration the crude product was purified by flash 
chromatography (100:2 CH2Cl2/MeOH) to give inseparable E/Z (3:1) mixture of 5e (410 mg, 
72%). Rf = 0.48 (CH2Cl2/MeOH 20:1). Mp > 200 °C (decomp.). IR (ATR/cm
-1): 2967, 2934 
(NH), 1719 (C=O), 1656, 1616, 1562 (C=N), 1332, 1244. HESI-Orbitrap MS: m/z for 
C27H34N6O4S2 [M+H]
+: calcd 571.21612, found 571.21406. 
(5e-E). 1H-NMR (500 MHz, DMSO-d6): 0.91 (s, 3H, H3C-18), 1.06 (qd, J = 13.5, 4.5 Hz, 1H, 
Hα-7), 1.12 (s, 3H, H3C-19), 1.26‒1.43 (m, 4H, H-9, Hα-12, H-14, Hβ-15), 1.56 (td, J = 13.5, 
4 Hz, 1H, Hα-1), 1.62‒1.88 (m, 4H, Hβ-1, Hβ-7, H-8, Hα-15), 2.01 (s, 3H, OCOCH3), 2.07‒
2.21 (m, 2H, Hβ-2, Hβ-12), 2.26‒2.34 (m, 1H, Hα-6), 2.36‒2.45 (m, 2H, Hβ-6, Hα-16), 2.50 
(m, 1H, Hβ-16, overlapped with DMSO), 2.93 (dt, J = 17, 3.5 Hz, 1H, Hα-2), 3.75 (s, 2H, H2-
5″), 3.795 (s, 2H, H2-5′), 5.15 (m, 1H, Hβ-11), 5.91 (s, 1H, H-4), 11.70 (br.s., 2H, 2NH). 13C 
NMR (125 MHz, DMSO-d6): 174.05 (s, C-4″), 173.95 (s, C-4′), 173.3 (s, C-17), 169.9 (c, 
OCOCH3), 162.2 (s, C-3), 162.2 (s, C-2″), 161.6 (s, C-2′), 157.1 (s, C-5), 122.2 (d, C-4), 70.5 
(d, C-11), 55.4 (d, C-9), 51.1 (d, C-14), 44.1 (s, C-13), 39.5 (s, C-10), 40.6 (t, C-12), 35.8 (t, C-
1), 34.3 (d, C-8), 32.8 (t, C-5′),  32.6 (t, C-5″), 32.4 (t, C-6), 31.0 (t, C-7), 28.0 (t, C-16), 22.9 
(t, C-15), 22.3 (t, C-2), 21.6 (q, OCOCH3), 18.3 (q, C-19), 17.5 (q, C-18). 
(5e-Z). 1H-NMR (500 MHz, DMSO-d6): 0.91 (s, 3H, H3C-18), 1.06 (qd, J = 13.5, 4.5 Hz, 1H, 
Hα-7), 1.17 (s, 3H, H3C-19), 1.26‒1.43 (m, 4H, H-8, Hα-12, H-14, Hβ-15), 1.62‒1.88 (m, 4H, 
Hα-1, Hβ-7, H-9, Hα-15), 2.02 (s, 3H, OCOCH3), 2.07‒2.21 (m, 3H, Hα-6, Hβ-6, Hβ-12), 2.26‒
2.34 (m, 1H, Hβ-2), 2.36‒2.45 (m, 2H, Hβ-1, Hα-16), 2.50 (m, 1H, Hβ-16, overlapped with 
DMSO), 2.93 (dt, J = 17, 3.5 Hz, 1H, Hα-2), 3.75 (s, 2H, H2-5″), 3.787 (s, 2H, H2-5′), 5.15 (m, 
1H, Hβ-11), 6.53 (s, 1H, H-4), 11.70 (br.s., 2H, 2NH). 13C NMR (125 MHz, DMSO-d6): 174.05 
(s, C-4″), 173.95 (s, C-4′), 173.3 (s, C-17), 169.9 (c, OCOCH3), 162.2 (s, C-2″), 161.6 (s, C-
2′), 159.6 (s, C-3), 158.6 (s, C-5), 115.0 (d, C-4), 70.3 (d, C-11), 55.6 (d, C-9), 51.0 (d, C-14), 
44.1 (s, C-13), 39.7 (s, C-10), 41.5 (t, C-12), 36.9 (t, C-1), 34.2 (d, C-8), 33.1 (t, C-6), 32.8 (t, 
C-5′),  32.6 (t, C-5″), 31.3 (t, C-7), 28.0 (t, C-16), 27.2 (t, C-2), 22.9 (t, C-15), 21.1 (q, 
OCOCH3), 18.3 (q, C-19), 17.5 (q, C-18). 
2.1.3.12. Pregn-4-ene-3,20-dione,3,20-bis[2-(4,5-dihydro-4-oxo-2-thiazolyl)hydrazone] (5f). 
After filtration the crude product was purified by flash chromatography (6:4 PhMe/EtOAc) to 
afford E/Z (3:1) mixture of 5f (366 mg, 68%) which could not be further separated. Rf = 0.23 
(toluene/EtOAc, 6:4). Mp = 275.0‒278.3 °C. IR (ATR/cm-1): 2966 (NH), 2932 (CH), 1714 
(C=O), 1632, 1616 (C=N), 1331, 1240, 1197. ESI-TOF-MS: m/z for C27H36N6O2S2 [M+2H]
2+: 
calcd 271.12433, found 271.12463; m/z for C24H30N6O2S2 [M+H]
+: calcd 541.24139, found 
541.24142. 
(5f-E). 1H-NMR (500 MHz, DMSO-d6): 0.61 (s, 3H, H3C-18), 0.85 (td, J = 11, 3 Hz,1H, H-9), 
0.93 (qd, J = 13, 3.5 Hz, 1H, Hα-7), 1.04 (s, 3H, H3C-19), 1.10‒1.24 (m, 2H, H-14, Hα-15), 
1.25‒1.35 (m, 3H, Hα-1, Hα-11, Hα-12), 1.45‒1.56 (m, 2H, H-8, Hβ-11), 1.57‒1.63 (m, 2H, 
Hβ-15, Hβ-16), 1.76 (m, 1H, Hβ-7), 1.83‒1.95 (m, 2H, Hβ-1, Hβ-12), 1.91 (s, 3H, H3C-21), 
2.09 (m, 1H, Hβ-2), 2.21‒2.28 (m, 2H, Hα-6, Hα-16), 2.29‒2.35 (m, 2H, Hβ-6, H-17), 3.01 (dt, 
J = 17, 3.5 Hz, 1H, Hα-2), 3.76 (s, 2H, H2-5″), 3.793 (s, 2H, H2-5′), 5.86 (s, 1H, H-4), 11.71 (s, 
2H, 2NH). 13C NMR (125 MHz, DMSO-d6): 173.8 (2s, C-4′ and C-4″), 165.3 (s, C-20), 162.0 
(s, C-3), 161.4 (s, C-2″), 161.3 (s, C-2′), 158.1 (s, C-5), 121.1 (d, C-4), 58.1 (d, C-17), 55.4 (d, 
C-14), 53.4 (d, C-9), 43.3 (s, C-13), 38.2 (t, C-12), 37.8 (s, C-10), 35.4 (d, C-8), 34.9 (t, C-1), 
32.7 (t, C-5′), 32.6 (t, C-5″), 31.9 (t, C-7), 31.8 (t, C-6), 23.8 (t, C-15), 23.1 (t, C-16), 22.0 (t, 
C-2), 20.9 (t, C-11), 19.0 (q, C-21), 17.4 (q, C-19), 13.0 (q, C-18). 
(5f-Z). 1H-NMR (500 MHz, DMSO-d6): 0.61 (s, 3H, H3C-18), 0.85 (td, J = 11, 3 Hz, 1H, H-9), 
0.93 (qd, J = 13, 3.5 Hz, 1H, Hα-7), 1.08 (s, 3H, H3C-19), 1.10‒1.24 (m, 2H, H-14, Hα-15), 
1.25‒1.35 (m, 2H, Hα-11, Hα-12), 1.40 (m, 1H, Hα-1), 1.45‒1.56 (m, 2H, H-8, Hβ-11), 1.57‒
1.63 (m, 2H, Hβ-15, Hβ-16), 1.76 (m, 1H, Hβ-7), 1.83‒1.95 (m, 2H, Hβ-1, Hβ-12), 1.91 (s, 3H, 
H3C-21), 2.16 (m, 1H, Hα-6), 2.24 (m, 1H, Hα-16), 2.28‒2.35 (m, 2H, Hβ-2, H-17), 2.37 (m, 
1H, Hβ-6), 2.41 (qd, J = 14.5, 3.5 Hz, 1H, Hα-2), 3.76 (s, 2H, H2-5″), 3.787 (s, 2H, H2-5′), 6.50 
(s, 1H, H-4), 11.70 (s, 2H, 2NH). 13C NMR (125 MHz, DMSO-d6): 173.9 (s, C-4′), 173.8 (s, C-
4″), 165.3 (s, C-20), 161.4 (s, C-2″), 161.3 (s, C-2′), 159.9 (s, C-5), 159.8 (s, C-3), 113.8 (d, C-
4), 58.0 (d, C-17), 55.3 (d, C-14), 53.6 (d, C-9), 43.3 (s, C-13), 38.5 (s, C-10), 38.2 (t, C-12), 
35.9 (t, C-1), 35.3 (d, C-8), 32.7 (t, C-5′), 32.6 (t, C-5″), 32.6 (t, C-6), 32.2 (t, C-7), 27.2 (t, C-
2),23.8 (t, C-15), 23.1 (t, C-16), 20.8 (t, C-11), 19.0 (q, C-21), 17.6 (q, C-19), 13.0 (q, C-18). 
2.2. Single crystal X-ray crystallography 
The crystal X-ray diffraction data for 4b-E were collected on a Gemini S diffractometer 
(Oxford Diffraction) with Mo Kα radiation (λ = 0.71073 Å) at room temperature. Data 
collection, reduction, and analytical absorption correction were performed with the 
CRYSALISPRO software [18]. Crystal structure was solved by using SHELXT [19] and refined 
by using SHELXL-2014 [20], with SHELXLE [21] as a graphical interface. 
All non-hydrogen atoms were refined anisotropically. The hydrogen atoms were placed at 
geometrically idealized positions with fixed bond lengths. Their isotropic displacement 
parameters were coupled to Ueq of the parent atoms. Absolute structure was assigned to match 
known absolute configuration of the steroid molecule. Occupational factor for water oxygen 
was refined to 0.475(2), and was fixed to 0.5 in the last refinement step. Hydrogen atoms 
belonging to the water molecule could not be located from difference density maps. 
The final results of crystal structure determination are summarized as follows. Molecular 
formula: C22H30N3O2.5S; Mr = 408.55; crystal system: orthorhombic; space group: P212121; unit 
cell parameters: a = 7.5223(3) Å, b = 9.7210(4), c = 28.8938(16) Å, V = 2112.84(18) Å3; Z = 
4; μ = 0.179 mm−1; 19050 reflections measured, 4949 unique reflections (Rint = 0.038); 99.9% 
data completeness up to 2θ = 52.64°, 91.1% data completeness up to 2θmax = 58.04°; 3699 
reflections with I > 2σ(I); number of refined parameters: 264; R1 = 0.054 for data with I > 2σ(I); 
wR2 = 0.174 for all data; goodness-of-fit S = 0.827; Flack x = 0.02(5) determined by Parsons’ 
quotient method [22]. 
Crystallographic data for 4b-E have been deposited with the Cambridge Crystallographic 
Data Centre as Supplementary publication No. CCDC 1541508. A copy of these data can be 
obtained, free of charge, via www.ccdc.cam.uk/data_request/cif, or by emailing 
data_request@ccdc.cam.ac.uk. 
2.3. Biology 
2.3.1. Cytotoxicity assay 
The cytotoxic activity of the compounds was evaluated against six human malignant cell 
lines: cervical adenocarcinoma (HeLa), chronic myelogenous leukemia (K562), breast 
carcinoma (MDA-MB-453), breast adenocarcinoma (MDA-MB-361), colon adenocarcinoma 
(LS174), lung carcinoma (A549), and one normal human cell line, lung fibroblasts (MRC-5). 
The cytotoxicity assay procedure has been described elsewhere [3,23]. Stock solutions of 
compounds were prepared in DMSO at a concentration of 10 mM. For each experiment, the 
solutions were diluted with nutrient medium and applied to cells to various final concentrations 
ranging from 6.25 μM to 100 μM or 12.50 μM to 200 μM. The final concentration of DMSO 
did not cause any toxicity to the cells. Survival of cells was determined by MTT assay after 72 
h of continuous action, according to the method of Mosmann [24], which was modified by 
Ohno and Abe [25] and described in detail in our previous studies [3-5, 23]. 
All tested cell lines were obtained from the American Type Culture Collection (Manassas, 
VA, USA). Cisplatin served as a positive control. 
The isolation and the treatment of human peripheral blood mononuclear cells (PBMC) were 
performed according to the previously reported procedure [26]. The applied concentrations of 
selected compounds ranged from 12.50 μM to 200 μM.  
The experiments on PBMC isolated from healthy blood donors were approved by the 
Ethics Committee of the Institute of Oncology and Radiology of Serbia. All healthy donors 
completed and signed written informed consent.  
2.3.2. Cell cycle analysis 
HeLa and K562 cells were treated with IC50 and 2IC50 concentrations of compounds 4a 
and 5a for 24 h and 48 h. After incubation, the cells were collected, washed and fixed in 70% 
ethanol, according to the standard procedure [23,26,27]. Cell cycle phase distributions were 
determined using a FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). 
The analysis of acquired data (10,000 events collected for each gated cell sample) was 
performed using a CELLQuest software (BD Biosciences). Cell cycle distribution data are 
presented as mean±S.D. of three independent experiments. The statistical significance of 
differences between the control and treated cell samples was evaluated using one-way ANOVA 
with Dunnett’s post test. p values below 0.05 were considered statistically significant.  
2.3.3. Morphological analysis by fluorescence microscopy 
To evaluate the mode of cell death induced by compounds 4a and 5a, morphological 
analysis by fluorescence microscopy of HeLa cells stained with a mixture of nucleic acid dyes 
acridine orange and ethidium bromide was performed, according to the previously described 
procedure [23,26]. The visualization was performed using Carl Zeiss PALM MicroBeam 
microscope with Axio Observer.Z1 and AxioCam MRm camera (filters: Alexa 488 and Alexa 
568, 20x magnification). 
2.3.4. Effects of specific caspase inhibitors 
To explore the effects of specific caspase inhibitors on the pro-apoptotic activity of 
compounds 4a and 5a in HeLa cells, the percentages of cells within the subG1 phase were 
measured by flow cytometry, as previously described [23,26]. The specific caspase inhibitors 
applied at a concentration of 40 µM included: Z-DEVD-FMK, a caspase-3 inhibitor, Z-IETD-
FMK, a caspase-8 inhibitor and Z-LEHD-FMK, a caspase-9 inhibitor (R&D Systems, 
Minneapolis, USA). 
2.3.5. Tube formation assay 
The potential antiangiogenic properties of compounds 4a and 5a were investigated on 
human umbilical vein EA.hy926 cell line using endothelial cell tube formation assay [28,29]. 
The in vitro angiogenesis assay was performed according to the previously described protocol 
[29]. The EA.hy926 cells seeded on Corning® Matrigel® basement membrane matrix (Corning: 
cat. number 356234) were treated with low sub-toxic IC20 concentrations of compounds 4a and 
5a (30 µM and 35 µM, respectively) for 20 h. Photomicrographs of EA.hy926 cells were 
captured under the inverted phase-contrast microscope using 6.3x magnification. 
2.3.6. Gene expression analyses 
HeLa cells were seeded in 75 cm2 cell culture flasks (4×106 cells/flask). After 24 h, the 
nutrient medium was removed, and cells were treated with low sub-toxic IC20 concentrations 
of compounds 4a and 5a (5 µM). Control cells were grown in nutruent medium. After a 24h 
incubation period, the cells were harvested by trypsinization and washed. The cell samples were 
then stored at ‒80°C  until further analyses. For the purpose of real-time-quantitative PCR (RT-
qPCR) analysis, total RNA was extracted from HeLa cells using TRI Reagent® (Sigma) 
according to the manufacturer`s instructions. RNA RIN was determined by Agilent RNA 6000 
Nano Kit (Agilent Technologies) on 2100 Bionalyzer and RNA concentration was determined 
spectrophotometrically (BioSpec Nano, Shimadzu). High-Capacity cDNA Reverse 
Transcription kit (Thermo Fisher Scientific) was used to prepare primary complementary DNA 
(cDNA) with random primers by RT-PCR. 2µg total RNA was used as a template for 
MultiScribeTM Reverse Transcriptase.  
Real Time quantitative PCR (RT-qPCR) 
Measurement of mRNA expression levels was done by quantitative real time PCR (qPCR) 
and Taqman assays. TaqMan® Gene Expression Assays (MMP2- Hs01548727_m1, MMP9- 
Hs00234579_m1 and VEGFA- Hs00900055_m1) consist of a 20X mix of unlabeled PCR 
primers and TaqMan® MGB probes (FAM™ dye-labeled). Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) for which data was obtained using TaqMan control reagents (Applied 
Biosystems- Hs02758991_g1) was used as an endogenous control. PCR reactions were 
performed using an ABI Prism 7500 Sequence Detection System (Applied Biosystems). The 
PCR reaction conditions were described previously [30].  
2.3.7. Free-radical scavenging antioxidant assay (DPPH method) 
The 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging activity was determined by 
the method of Blois [31]. Tested compounds were dissolved in pure DMSO.  
Ascorbic acid (AA) was used as the reference compound (positive control) with concentrations 
from 50‒500 mg mL-1. 
3. Results and Discussion 
3.1. Chemistry 
New steroidal mono- and bis(thiazolidin-4-ones) 4a‒f and 5a‒f were obtained in good 
yields (51-86%) as shown in Scheme 1 by intermolecular cyclocondensation reaction of 
thiosemicarbazones 2a‒f and 3a‒f [3] with ethyl chloroacetate in boiling absolute ethanol 
containing anhydrous sodium acetate [17]. The reaction conditions were optimized by varying 
amount of ethyl chloroacetate and anhydrous sodium acetate and duration of the reaction. The 
highest yields were obtained when reaction was carried out with small excess of anhydrous 
sodium acetate (1:1.5 and 1:3 equiv.) and with one and two equivalents of cyclization reagent 
for mono- and bis(1,3-thiazolidin-4-ones) 4a‒f and 5a‒f during 24 and 45 h, respectively. 
As it was reported in our previous paper [3], thiosemicarbazones 2a‒f and 3a‒f were 
obtained as inseparable mixtures of isomers (E/Z) differing in configuration in the hydrazone 
moiety at the C-3 position. Since the cyclization reaction of these thiosemicarbazones does not 
affect the C(3)=N1 double bond, all mono- and bis(thiazolidin-4-ones) 4a‒f and 5a‒f were also 
obtained as stereoisomeric mixtures. This time, we were more fortunate and after several 
consecutive crystallizations diastereomerically pure major (E)-isomers of 4a‒f were isolated. 
As all our attempts to get the pure minor isomers had failed, their structures were determined 
on the basis of the spectral data (1H NMR, 13C NMR) for the mixtures. 
Besides C(17)=O/C(20)=O carbonyl bands (at about 1730/1700 cm–1) the IR spectra of 4a–
f showed the absorption bands for the new lactam C=O group at 1717‒1725 cm–1. Also, all 
compounds showed stretches at 1612–1628 cm–1 that were assigned to C═N vibrations, and 
intense bands at 1239–1252 cm–1 attributed to the v(CH2–S) stretching vibration, all confirming 
the formation of thiazolidinone ring. 
In the 1H NMR spectra the signals for the amino groups from the starting 
thiosemicarbazones 2a‒f were missing. Instead, the new signals for  the methylene protons at 
C-5′ of the thiazolidinone ring moiety appeared in the range of δ 3.787‒3.795 ppm for (E)-
isomers and at δ 3.770‒3.789 ppm for (Z)-isomers of 4a–f. Also, the singlets for H-4 proton at 
about δ 6.50 ppm for all (Z)-isomers of 4a–f were situated downfield from the resonance for 
the corresponding proton in the starting (Z)-thiosemicarbazones 2a‒f, which was atributed to 
the C(4′)=O carbonyl group anisotropy due to the position of the thiazolidinone ring. The signal 
for the same proton in (E)-isomers appeared at about δ 5.85 ppm. In addition, in all (E)-
thiazolidinones, Hα-2 protons resonate well-separated downfield from the other ring protons as 
a dt at about δ 3.00 ppm. The signals for NH appeared at about δ 11 ppm.  
The 13C NMR spectra of 4a–f displayed characteristic signals of the 4-thiazolidinone 
skeleton: at δ 173.8 ppm for C-4′ carbonyl in both isomers, at δ 161.2–161.7 ppm for C(2′)=N 
in (E)-isomers and at δ 159.5–161.4 ppm for C(2′)=N in (Z)-isomers, and at δ 32.5–33.2 ppm 
for methylene C-5′ carbons. The other characteristic signals were: at δ 121.2–122.4 ppm and 
111.8–115.2 ppm (C-4), 161.8–163.5 ppm and 159.5–161.5 ppm (C-3), 153.6–158.7 ppm and 
155.4–160.3 ppm (C-5) for 4a–f-E and 4a–f-Z, respectively. 
Finally, the molecular formulas of 4a‒f were deduced from the HR mass spectra that 
have shown molecular weights of obtained compounds 40 Da higher compared to 
molecular weights of the parent thiosemicarbazones (2a‒f). 
In the absence of any NOESY correlations the X-ray analysis of 4b-E was used to 
confirm the structure of the major isomer of 4a‒f and its geometry (Figure 2). The 
compound crystalize in non-centrosymmetric space group P212121. The absolute 
structure has been unequivocally assigned by known chirality of steroidal carbon atoms, 
and is also in agreement with absolute structure parameter Flack x = 0.02(5), determined 
by Parsons’ quotient method [22]. The steroidal core adopts the expected conformation, 
i.e. rings B and C are in chair conformations C5CC8 and 
C9CC13, respectively, while five-
membered ring D adopts envelope conformation C14E [32]. As expected, due to sp2 
hybridization of C3, C4, and C5 atoms, and presence of C4–C5 double bond (1.335(5) 
Å), the ring A is in half-chair conformation C2HC1. This can be quantified by asymmetry 
parameters [33], which have values C2(C1–C2) = C2(C4–C5) = 0.9(5)°, and by torsion 
angle τ(C3–C4–C5–C10) = −5.0(6)°. 
It is noteworthy to say that, up to now, there is only one structurally characterized 
compound with cyclohexene-3-ylidenehydrazono-thiazolidin-4-one fragment [34]. The 
geometry of thiazolidin-4-one ring is in accordance with structural data of compounds 
containing hydrazono-thiazolidin-4-one fragment, retrieved from the CSD [35]. The sulfur 
atom S1′ is asymmetrically bonded with two carbon atoms in a way that bond with sp2 
hybridized C2′ is shorter (1.751(4) Å) than bond with sp3 hybridized C5′ (1.812(5) Å). Also, 
the bond length C4′–O2 (1.216(5) Å) corresponds to localized double bond. The thiazolidin-4-
one ring is roughly coplanar with C5–C4–C3–N1–N2 fragment of sp2 hybridized atoms. 
However, closer inspection shows that the ring is slightly puckered by small displacement of 
S1′ atom from the ring plane. The nature and amount of puckering is evident through Cremer–
Pople parameters Q2 = 0.100(4) Å and φ2 = 2(3)° [36]. Based on these data and asymmetry 
parameters Cs(S1′) = Cs(C4′–N3′) = 1.5(5)°, its conformation is best described as envelope S1′E. 
The bond lengths C3–N1 and C2′–N2 correspond to the localized double bonds between 
respective atoms. Structural data revealed E-configuration around C3–N1, and Z-configuration 
around C2′–N2 double bonds, which can be expressed through torsion angles τ(C4–C3–N1–
N2) = −179.9(3)° and τ(N1–N2–C2′–S1′) = −2.7(5)°, respectively. To the best of our 
knowledge, this is the first steroidal derivative containing C3-bonded hydrazono-thiazolidin-4-
one fragment with known configuration of double bonds. 
The dominant intermolecular interaction in the crystal structure is N3′–H3···O2i hydrogen 
bond, which connects molecules in chains along crystallographic axis a (Fig. S1), with graph 
set descriptor C1
1(4) [37] (hydrogen bond data: N3′–H3 = 0.86 Å, H3···O2i = 2.05(4) Å, 
N3′···O2i = 2.903(5) Å, (N–H···O3i) = 170.1°; symmetry code (i): 1/2+x, 1/2−y, 1−z). 
Molecular formulas of bis(thiazolidin-4-ones) 5a‒f deduced from their HR mass spectra 
showed that the molecular weights of these compounds were 80 Da higher than ones of parent 
bis(thiosemicarbazones) 3a‒f and 113 Da higher than the molecular weights of 4a‒f. This 
indicates that compounds 5a‒f have one more thiazolidinone moiety. Also, in the IR spectra of 
5a‒f all the characteristic absorption bands for thiazolidinone ring were present. 
As in the case of parent bis(thiosemicarbazones) 3a‒f, the NMR spectral data of 5a‒f 
revealed the existence of two diastereoisomers differing only in the configuration around 
C(3)=N1 double bond while at C-17/C-20 position only one isomer occured. The 1H NMR 
spectra of 5a‒f showed singlets at δ 3.74, 3.74, 3.76, 3.76, 3.75 and 3.76 ppm, respectively, for 
the methylene protons at C-5″ (4-thiazolidinone ring at C-17/C-20) in both isomers. Also, the 
singlets for CH3-18 protons appeared at the same value for both isomers, as well as the signals 
for Hα-16 and Hβ-16. Furthermore, the 13C NMR spectra showed single characteristic signals 
at δ 178.6, 178.5, 178.5, 177.9, 173.3 and 165.3 ppm for C-17, at δ 174.4, 173.8, 173.9, 174.0, 
174.05, 173.8 ppm for C-4″ carbonyl and at 161.8, 161.4, 161.5, 161.8, 161.2 and 161.4 ppm 
for C-2″ in compounds 5a‒f, respectively. Regarding other signals, almost the same patterns of 
1H and 13C NMR spectra were observed as in the spectra for compounds 4a-f. 
 The proposed mechanism of the formation of these new steroidal thiazolidin-4-one is as 
follows (Scheme 2). First step involves S-alkylation of thiosemicarbazones 2a‒f and 3a‒f in 
thiol form (due to the sodium acetate used). This step is followed by a nucleophilic attack by 
NH2 on carbon atom of carbonyl group and ethanol removal, resulting in formation of 4-
thiazolidinones 4a‒f and 5a‒f. The excess of sodium acetate was used to scavenge the hydrogen 
chloride, whereas ethyl chloroacetate acts as the cyclizing agent. 
3.2. Cytotoxic activity 
The in vitro cytotoxic activity of all newly synthesized compounds 4a‒f and 5a‒f was 
tested against six human malignant cell lines (HeLa, K562, MDA-MB-453,  MDA-MB-361, 
LS174 and LS174 ) and and one normal human cell line  (MRC-5). Cisplatin was employed as 
the positive control. The data summarized in Table 1 indicate that all given compounds exerted 
cytotoxic action at micromolar concentrations on investigated malignant cell lines, especially 
strong towards K562 cells, which showed the highest sensitivity to the cytotoxic action of these 
new steroid derivatives. Against this cell line compounds 4a‒d, 4f, 5a‒d and 5f showed a strong 
cytotoxic activity with IC50 values of 8.8, 8.7, 8.8, 11.3, 8.7, 8.9, 10.5, 9.6, 11.6 and 14.9 µM, 
respectively, while the other two compounds 4e and 5e were slightly less active with IC50 values 
of 19.2 and 21.9 µM, respectively. Compounds, 4a‒c, 4f, 5a‒c and 5f exhibited a strong 
cytotoxic action against HeLa cells with IC50 values of 8.9‒15.1 µM. This cell line 
demonstrated a moderate sensitivity (IC50 values from 28.0‒51.4 µM) against all other 
compounds. Almost all new steroid derivatives, with the exception of 4d and 5d, showed good 
to moderate activity against both breast cancer cell lines, with IC50 values from 10.7‒46.7 µM. 
However, it must be noted that compounds 4a, 4b, 4c, 4f, 5c and 5f exerted similar or even 
better cytotoxic action (IC50 values of 12.7, 25.6, 19.6, 14.5, 24.6 and 20.6 µM, respectively) 
against MDA-MB-361 cells compared to cisplatin (21.5 µM).  A549 cells were sensitive to the 
cytotoxic actions of 4a, 4f, 5a‒c and 5f which showed cytotoxic activity comparable to one of 
cisplatin, with IC50 values in the range of 17.2‒27.6 µM. Moreover, the activity of these 
compounds was almost three times lower against lung fibroblasts MRC-5 cell line with IC50 
values from 31.4‒62.7 µM. The colorectal adenocarcinoma LS174 cells were the least sensitive 
to all tested compounds, except towards 5b and 5f the activity of which was the same or even 
higher in comparison to cisplatin, with IC50 values of 21.8 and 11.0 µM, respectively. 
The results mentioned above demonstrate that mono-thiazolidinones 4a, 4b, 4c and 4f 
exhibited the highest cytotoxic activities against all cell lines tested, in some cases higher than 
corresponding starting thiosemicarbazones 2a–c and 2f [3]. The activity of bis-thiazolidinones 
5a–f, although slightly lower, was notably higher in comparison to corresponding bis-
thiosemicarbazones 3a–f, which were found to be practically inactive against almost all 
examined cancer cell lines [3]. Moreover, even the least active 11α-substituted derivatives 4d, 
4e, 5d and 5e, showed much more pronounced cytotoxicity than parent thisemicarbazone 
derivatives. This pointed to the fact that this type of heterocyclization of thiosemicarbazone 
moiety at C-3 and especially at C-17 and/or C-20 position enhanced the anticancer activity of 
the investigated steroid compounds.  
If we consider the type of steroid units it is clear that 3-mono-thiazolidinones 4a, 4b, 4c 
and 4f displayed similar anticancer actions against most of the cell lines used in this study. This 
which corroborates our previous finding that the absence of 19-methyl group, the degree of 
unsaturation or the substituent at C-17 (17-oxo or 17-COCH3) does not affect their cytotoxicity 
significantly [3]. Also, bis-thiazolidinones 5a, 5b, 5c and 5f were found to behave the same 
way. The exceptions were again the derivatives of 11α-hydroxyandrost-4-ene-3,17-dione, 4d 
and 5d, which were the least active against malignant cell lines tested. Since the introduction 
of OCOCH3 instead of OH group (compounds 4e and 5e) significantly improved the activity of 
these compounds, the data obtained in this study support our previous results [3] that the 
replacement of 11α-hydrogen by the proton-donating substituent decreases the activity of tested 
steroid compounds. 
Summarizing the results it can be concluded that α,β-unsaturated substituent at C-3 and 
substituent at C-17 and/or C-20 position and their heterocyclic 4-thiazolidinone moieties are 
mostly responsible for the anticancer activity of the new synthesized steroid derivatives. 
Since in our previous report [3] steroidal thiosemicarbazones 2a‒f and 3a‒f were obtained 
as inseparable steroisomeric mixtures it could not be determined which geometric isomer had 
a greater cytotoxic action on malignant cells used in the study. Due to the fact that in this work, 
diastereomerically pure major, (E)-isomers, of most of the thiazolidinones (4a‒c and 4f) were 
successfully isolated, it was possible to compare the activity of pure (E)-isomers with the 
activity of the mixtures. Examining the IC50 values in Table 1, it can be concluded that there 
were no significant differences in cytotoxicity of (E/Z)-mixtures and pure (E)-isomers, 
indicating that the configuration around C(3)=N1 double bond had no influence on the activity 
of these compounds. For this reason, and also for better comparison of the activity of these 
compounds with the activity of previously synthesized thiosemicarbazones [3] and newly 
synthesized bis-thiazolidinones 5a-f (obtained only as (E/Z) mixtures), all further experiments 
were carried out with the mixtures. 
The compounds which exerted the most pronounced cytotoxic action were selected for 
further examination of cytotoxicity against normal, non-transformed human peripheral blood 
mononuclear cells (PBMC), both unstimulated and stimulated to proliferate by the mitogen 
phytohemagglutinin (PHA) (Table 2). 
Each of the tested compounds (4a‒c, 4f, 5a‒c and 5f) exhibited notably higher cytotoxic 
activities against all cell lines, especially against HeLa, K562, MDA-MB-453 and MDA-MB-
361 cells in comparison with resting and PHA-stimulated PBMC. In all cases the action of 
tested compounds was less pronounced on unstimulated than upon stimulated PBMC.  
The selectivity in the antitumor action of all investigated compounds was very high for 
both K562 and HeLa cell lines which were the most sensitive to their cytotoxic effects. It must 
be noted that compounds 4a, 4b, 5a, 5c and 5f also displayed a very good selectivity in the 
anticancer effect against human breast carcinoma MDA-MB-453 and MDA-MB-361 cells and 
against A549 cells. In addition, compound 5f showed much higher intensity  of cytotoxic action 
against LS174 cells than against normal immunocompetent PBMC (Table 3). 
Effective and selective killing of cancer cells, while exerting minimal toxicity to normal, 
non-transformed cells, and especially to immune system cells, involved in the antitumor 
immune response are highly desirable properties for development of novel anticancer 
compounds. Therefore, very good selectivity in the cytotoxic activity of the examined steroidal 
thiazolidin-4-one derivatives against cancer cells (especially high against K562 and HeLa cells) 
when compared with normal human PBMC suggests their promising anticancer potential. The 
most potent compounds, 4a and 5a were selected for a further biological evaluation.  
The mechanisms of their anticancer activity were further examined by cell cycle analysis 
and fluorescence microscopy. Both tested compounds applied at IC50 and 2IC50 concentrations 
for 24 h and 48 h induced a significant increase of human cervical adenocarcinoma HeLa cells 
in the subG1 and G2/M cell cycle phases when compared with the control cell sample (Fig. 3). 
These alterations were accompanied with significantly decreased proportion of treated HeLa 
cells in G1 phase. In addition, the exposure to compound 4a at 2IC50 concentration for 24 h and 
to IC50 concentration for 48 h led to significant accumulation of HeLa cells in the S phase, while 
the S phase arrest was observed in HeLa cells treated with compound 5a at both tested 
concentrations after 24 h and 48 h exposure. 
In human myelogenous leukemia K562 cells, treatment with IC50 and 2IC50 concentrations 
of compound 4a for 24 h and 48 h caused a statistically significant increase in the percentage 
of cells within the subG1 cell cycle phase in addition to significant G2/M cell cycle phase arrest 
in comparison with untreated cells (Fig. 4). The significantly decreased percentages of K562 
cells in the G1 and S phases were observed as well. Compound 5a at both tested concentrations 
induced a significant accumulation of K562 cells in the subG1 and G2/M cell cycle phases 
when compared to the control cell sample. The significantly decreased percentage of K562 cells 
in the G1 phase was demonstrated as well, while the reduction of cells in the S phase was 
statistically significant only after treatment that lasted 24 h. 
Fluorescence microscopy visualization of HeLa cells stained with a mixture of nucleic acid 
dyes acridine orange and ethidium bromide demonstrated pro-apoptotic effects of compounds 
4a and 5a (Fig. 5). The exposure to 2IC50 concentrations of compounds 4a and 5a for 24 h led 
to an appearance of typical morphological characteristics of apoptotic cell death such as green 
stained rounded HeLa cells with condensed chromatin and shrunken nuclei as well as orange-
red stained late apoptotic cells. However, the rounded shape of treated HeLa cells could also be 
attributed to G2/M arrest induced by the tested compounds, as observed by cell cycle analysis. 
To investigate the mechanisms of the pro-apoptotic activity of compounds 4a and 5a, the 
specific inhibitors of caspase-3, -8 and -9 were used for cell cycle analysis. Pretreatment with 
a caspase-3 inhibitor remarkably decreased the percentage of HeLa cells exposed to compounds 
4a and 5a in sub G1 phase when compared to exposed cells that were not pretreated with an 
inhibitor, pointing to the ability of compounds to activate the effector caspase-3 in the apoptotic 
pathway (Fig. 6). Reduction of the percentage of HeLa cells in the subG1 phase, which were 
pre-exposed to caspase-8 or caspase-9 inhibitor before treatment with 4a and 5a, was found 
when compared with treated HeLa cells which were not pretreated with inhibitors. These results 
indicate that both compounds trigger extrinsic and intrinsic apoptotic signaling pathways in 
HeLa cells. 
The endothelial cell tube formation assay demonstrated anti-angiogenic effects of 
compounds 4a and 5a applied at low sub-toxic concentrations as shown in Fig. 7. Both 
examined compounds were able to inhibit sprouting and connecting of EA.hy926 cells and 
formation of capillary-like tube structures, suggesting their anti-angiogenic potential. 
To further explore the possible antimetastatic and anti-angiogenic properties of novel 
steroidal thiazolidin-4-one derivatives, the effects of compounds 4a and 5a on gene expression 
levels of MMP2, MMP9 and VEGFA in HeLa cells were examined. Gene expression levels in 
treated HeLa cells were compared to the control cells (Fig. 8).The treatment with 4a and 5a 
barely affected MMP2 and MMP9 expression levels when compared to those levels in control 
HeLa cells. In addition, these compounds did not induce considerable alterations in gene 
expression profile of the pro-angiogenic growth factor VEGFA in HeLa cells.  
To the best of our knowledge, the present research is the first to report the selective 
cytotoxic activities of novel steroidal thiazolidinone derivatives on human cancer cell lines, 
their ability to induce apoptosis and G2/M phase arrest in human cervical adenocarcinoma 
HeLa cells, in addition to inhibition of angiogenesis of EA.hy926 cells. This study represents 
significant contribution to the research efforts to elucidate the mechanisms of anticancer activity 
of compounds bearing 4-thiazolidinone bioactive scaffold. 
The ability of investigated steroid derivatives to scavenge radicals was investigated by the 
DPPH test (Table 4). The results showed that compounds 4a, 4e, 4f, 5a, 5d and 5e have some 
antioxidant activity, although much weaker than ascorbic acid. 
4. Conclusion 
New steroidal mono- and bis(thiazolidin-4-ones) 4a‒f and 5a‒f were efficiently 
synthesized by intermolecular cyclocondensation reaction of corresponding 
thiosemicarbazones 2a‒f and 3a‒f and ethyl chloroacetate as cyclizing reagent. All compounds 
were obtained as stereoisomeric mixtures with different configuration in the hydrazone moiety 
at the C-3 position. Diastereomerically pure major (E)-isomers of mono-thiazolidin-4-ones 4a‒
f were successfully isolated. The structure and stereochemistry were confirmed by X-ray 
analysis of 2,4-thiazolidinedione,2-[(17-oxoandrost-4-en-3-ylidene)hydrazone] (4b). A 
pathway for the formation of thiazolidin-4-one ring was proposed. 
The newly synthesized thiazolidinone derivatives exerted selective concentration-
dependent cytotoxic action toward malignant cell lines tested. The introduction of heterocyclic 
4-thiazolidinone moieties at C-3 and especially at C-17 and/or C-20 position enhanced the 
anticancer activity of the investigated steroid compounds. HeLa and K562 cells were the most 
sensitive to the cytotoxic effects of these compounds. Ten out of twelve examined compounds 
exhibited strong cytotoxic effects on K562 cells with IC50 values of  8.5‒14.9 µM, eight on 
HeLa cells with IC50 values of 8.9‒15.1 µM, while against MDA-MB-361 cells six compouds 
exerted similar or even higher cytotoxic action than cisplatin with IC50 values from 12.7 µM to 
25.6 µM. On the contrary, a very low toxic effect upon both non-stimulated, and PHA 
stimulated PBMCs has been detected. Moreover, eight of these ten compounds showed very 
high selectivity in the cytotoxic action, especially against HeLa and K562 cancer cell lines.The 
mechanisms of the anticancer activity of the two selected compounds, mono- and 
bis(thiazolidin-4-one) derivatives of 19-norandrost-4-ene-3,17-dione 4a and 5a, were further 
elucidated. Both examined compounds applied at 2IC50 concentrations (17.8 µM and 27.0 µM, 
respectively) for 24 h induced a significant increase of HeLa cells in the subG1, S and G2/M 
cell cycle phases compared to the control cell sample. Morphological analysis by fluorescence 
microscopy of HeLa cells stained with a mixture of acridine orange and ethidium bromide 
revealed pro-apoptotic effects of these compounds. In addition, both compounds demonstrated 
the ability to trigger apoptosis in HeLa cells through extrinsic and intrinsic signaling pathways. 
Treatment of EA.hy926 cells, grown on the surface of matrigel, with sub-toxic concentrations 
of compounds 4a and 5a for 20 h, led to the inhibition of cell connecting and sprouting, and 
tube formation. The compounds 4a and 5a did not cause significant changes in MMP2, MMP9 
and VEGFA gene expression levels in HeLa cells. 
Our results suggest the significant anticancer potential of newly synthesized steroid 
thiazolidinone derivatives due to their strong cytotoxicity against malignant cells, good 
selectivity and antiangiogenic effects. 
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Figure captions 
Scheme 1. Synthesis of new steroidal mono- and bis(thiazolidin-4-ones) 4a‒f and 5a‒f.  
 
Scheme 2. The proposed mechanism of the formation 4-thiazolidinones 4a‒f and 5a‒f  
Figure 1. Previously synthesized mono- and bis(thiosemicarbazones) 2a‒f and 3a‒f obtained 
from androstene derivatives 1a‒f.  
Figure 2. Molecular structure of 4b-E with atom numeration.  
Anisotropic displacement ellipsoids are drawn at 50% probability level. Hydrogen atoms are 
depicted as spheres of arbitrary radius. Selected bond lengths (Å): S1′–C2′ = 1.751(4), S1′–C5′ 
= 1.812(5), O2–C4′ = 1.216(5), N3′–C2′ = 1.367(5), N3′–C4′ = 1.369(6), C4′–C5′ = 1.501(6), 
N2–C2′ = 1.283(5), N1–N2 = 1.398(5), N1–C3 = 1.308(5), C3–C4 = 1.452(5), C4–C5 = 
1.335(5). Selected torsion angles (°):   C3–C4–C5–C10 = −5.0(6)°, C4–C3–N1–N2 = 
−179.9(3)°, N1–N2–C2′–S1′ = −2.7(5)°. 
Figure 3. Changes in the cell cycle phase distribution of HeLa cells  
Changes in the cell cycle phase distribution of cervical adenocarcinoma HeLa cells, induced by 
the investigated compounds 4a and 5a after 24 h (A, B) and 48 h (C, D) treatment. Applied 
concentrations of tested compounds corresponded to IC50 (A, C) and 2IC50 (B, D) values 
determined for 72 h. The data shown represent the mean ± S.D. of three independent 
experiments. Significant differences between cell cycle distribution of control and treated cells 
are indicated by * (p < 0.05) 
Fig. 4. Changes in the cell cycle phase distribution of K562 cells  
Changes in the cell cycle phase distribution of myelogenous leukemia K562 cells, induced by 
the investigated compounds 4a and 5a after 24 h (A, B) and 48 h (C, D) treatment. Applied 
concentrations of tested compounds corresponded to IC50 (A, C) and 2IC50 (B, D) values 
determined for 72 h. The data shown represent the mean ± S.D. of three independent 
experiments. Significant differences between cell cycle distribution of control and treated cells 
are indicated by * (p < 0.05) 
Figure 5. Induction of apoptosis in HeLa cells by compounds 4a and 5a  
Photomicrographs of acridine orange/ethidium bromide-stained control HeLa cells and HeLa 
cells exposed to 2IC50 concentrations of the compounds 4a and 5a for 24 h. Typical 
morphological characteristics of apoptotic cell death are green stained rounded HeLa cells with 
condensed chromatin and shrunken nuclei as well as orange-red stained late apoptotic cells. 
Magnification 20x. 
Figure 6. Identification of target caspases involved in the apoptotic signaling pathways induced 
by the compounds 4a and 5a  
Effects of the specific caspase inhibitors (Z-DEVD-FMK - caspase-3 inhibitor; Z-IETD-FMK 
-caspase-8 inhibitor; Z-LEHD-FMK - caspase-9 inhibitor) on the percentages of subG1 HeLa 
cells treated with 2IC50 concentrations of the compounds 4a (A) and 5a (B). 
Figure 7. Anti-angiogenic effects of compounds 4a and 5a 
Photomicrographs of control EA.hy926 cells and EA.hy926 cells exposed to sub-toxic IC20 
concentrations of the compounds 4a and 5a for 20 h. Both examined compounds were able to 
inhibit sprouting and connecting of EA.hy926 cells and formation of capillary-like tube 
structures. Photomicrographs were captured under the inverted phase-contrast microscope 
using 6.3x magnification. 
Figure 8. Gene expression levels of MMP2 (A), MMP9 (B) and VEGFA (C) in control HeLa 
cells and HeLa cells exposed to sub-toxic IC20 concentrations of the compounds 4a and 5a for 
24 h. 
  
Figr-1  
  
Figr-2  
  
Figr-3  
  
Figr-4  
  
Figr-5  
  
Figr-6  
  
Figr-7  
  
Figr-8  
  
Table 1. Concentrations of investigated compounds 4a‒f and 5a‒f which induced 50% decrease 
(IC50) in malignant cell survival 
Comp. 
 IC50 ± SD (µM) 
HeLa K562 MDA-MB-453 MDA-MB-361 LS174 A549 MRC-5 
4a-E 9.2 ± 2.3 8.5 ± 0.9 22.2 ± 2.4 10.7 ± 0.4 49.5 ± 6.7 22.0 ± 5.0 60.9 ± 6.8 
4a-E/Z 8.9 ± 1.9 8. 8 ± 1.1 23.7 ± 2.7 12.7 ± 2.0 48.2 ± 4.9 22.3 ± 4.7 62.7 ± 6.2 
4b-E 10.8 ± 1.9 9.1 ± 1.3 24.9 ± 0.2 22.0 ± 0.8 48.2 ± 2.5 48.6 ± 1.9 55.7 ± 8.0 
4b-E/Z  10.7 ± 2.5 8.7 ± 1.1 23.8 ± 1.7 25.6 ± 4.6 49.7 ± 0.5 49.5 ± 0.6 44.8 ± 7.3 
4c-E 9.8 ± 1.1 9.4 ± 1.7 27.1 ± 0.1 19.1 ± 2.3 51.8 ± 9.0 42.1 ± 3.8 53.2 ± 7.0 
4c-E/Z 9.5 ± 0.9 8.8 ± 1.2 26.2 ± 2.7 19. 6 ± 2.2 51.3 ± 3.2 40.4 ± 7.5 49.9 ± 9.3 
4d-E/Z 51.4 ± 10.5 11.3 ± 2.9 116.0 ± 11.8 134.0 ± 7.9 119.9 ± 25.9 176.1 ± 9.5 111.4 ± 20.1 
4e-E/Z 28.0 ± 5.2 19.2 ± 0.4 29.4 ± 4.1 29.6 ± 1.6 104.5 ± 8.7 77.7 ± 26.8  88.4 ± 17.2 
4f-E 8.9 ± 1.7 8.7 ± 0.3 21.5 ± 2.8 14.5 ± 5.3 49.1 ± 2.8 18.6 ± 6.6 42.8 ± 2.2 
5a-E/Z 13.5 ± 0.1 8.9 ± 1.1 30.9 ± 6.2 36.0 ± 6.3 42.6 ± 6.4 25.3 ± 4.0 58.1 ± 2.6 
5b-E/Z 12.9 ± 2.9 10.5 ± 1.3 37.3 ± 2.5 30.2 ± 7.3 21.8 ± 5.1 27.6 ± 7.2 53.4 ± 9.0 
5c-E/Z 11.2 ± 1.6 9.6 ± 1.7 33.5 ± 6.3 24.6 ± 0.4 47.8 ± 3.9 24.9 ± 0.2 48.8 ± 1.6 
5d-E/Z 41.2 ± 2.7 11.6 ± 2.1 77.1 ± 4.1 86.8 ± 2.6 73.0 ± 10.0 76.2 ± 4.0 91.1 ± 9.9 
5e-E/Z 31.3 ± 3.8 21.9 ± 5.1 46.7 ± 9.0 39.5 ± 5.3 36.4 ± 5.6 39.8 ± 3.3 67.9 ± 9.5 
5f-E/Z 15.1 ± 6.1 14.9 ± 3.8 23.9 ± 0.2 20.6 ± 1.0 11.0 ± 1.3 17.2 ± 4.6 31.4 ± 4.9 
cisplatin   5.2 ± 05 5.7 ± 0.6 6.5 ± 0.5 21.5 ± 1.5 18.6 ± 2.0 17.4 ± 1.8 13.0 ± 1.7 
 
  
Table 2. Concentrations of compounds 4a‒c, 4f, 5a‒c and 5f  which induced 50% decrease 
(IC50) in PBMC and PBMC+ PHA cell survival 
Comp. 
IC50  ± SD (µM) 
PBMCa PBMC+PHAa 
4a       145.8 ± 2.5   92.1 ± 14.3 
4b            ˃200 155.7 ± 13.3 
4c       123.4 ± 4.4 64.4 ± 7.1 
4f   88.6 ± 11.6 64.7 ± 8.0 
5a       188.8 ± 15.9 88.1 ± 8.6 
5b         87.1 ± 0.5   59.8 ± 14.0 
5c            ˃200 188.7 ± 16.0 
5f      123.8 ± 12.1 62.3 ± 7.6 
cisplatin        71.3 ± 8.20 32.9 ± 3.7 
aFrom two independent experiments (healthy blood donors) 
 
  
Table 3. Coefficient of selectivity (Cs) in antitumor action of compounds 4a‒c, 4f, 5a‒c and 5f 
as a ratio of IC50 values for PBMC (PBMC+PHA) and malignant cells  
 
Comp. 
             Cs   
PBMC 
(PBMC+PHA)/ 
HeLa 
PBMC 
(PBMC+PHA)/ 
K562 
PBMC  
(PBMC+PHA)/ 
MDA-MB-453 
PBMC 
(PBMC+PHA)/ 
MDA-MB-361 
PBMC 
(PBMC+PHA)/ 
LS174 
PBMC  
(PBMC+PHA)/ 
A549 
4a 
16.3 
 (10.3) 
16.6  
(10.5) 
6.2 
 (3.9) 
11.5  
(7.3) 
3  
(1.9) 
6.5 
 (4.1) 
4b 
>18.6  
(4.5) 
>23  
(17.9) 
>8.4 
 (6.6) 
>7.8  
(6.1) 
>4  
(3.1) 
>4 
 (3.1) 
4c 
13  
(6.8) 
14  
(7.3) 
4.7  
(2.5) 
6.3  
(3.3) 
2.4 
 (1.3) 
3.1  
(1.6) 
4f 
10  
(7.3) 
10.2  
(7.5) 
4.1 
 (3) 
6.1  
(4.5) 
1.8 
 (1.3) 
4.8 
 (3.5) 
5a 
14  
(6.5) 
21.3  
(9.9) 
6.1 
 (2.8) 
5.2  
(2.4) 
4.4  
(2.1) 
7.5  
(3.5) 
5b 
6.7 
 (4.6) 
8.3 
 (5.7) 
2.3 
 (1.6) 
2.9 
 (2) 
4  
(2.7) 
3.2 
 (2.2) 
5c 
>17.8 
 (6.8) 
>20.8 
 (19.6) 
>6 
 (5.6) 
>8.1 
 (7.7) 
>4.2  
(3.9) 
>8  
(7.6) 
5f 
8.2  
(4.1) 
8.3 
 (4.2) 
5.2 
 (2.6) 
6  
(3) 
11.3 
 (5.7) 
7.2 
 (3.6) 
cisplatin 
13.6 
 (6.3) 
12.6  
(5.8) 
11.1 
 (5.1) 
3.3 
 (1.5) 
3.8 
 (1.8) 
4.1 
 (1.9) 
 
 
  
Table 4. Antioxidant activity (IC50/mM) of compounds 4a‒f and 5a‒f  
Comp. 4a 4b 4c 4d 4e 4f 5a 5b 5c 5d 5e 5f AA * 
IC50 (mM) 18.83 / / / 4.33 40.48 17.54 / / 10.06 42.48 / 0.08 
*Ascorbic acid 
 
 
